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1. INTRODUCTION 
 
Synthetic organic chemistry is based on the concourse of reagents and catalysts to achieve the 
clean formation of new bonds and appropriate protecting groups are required to prevent the 
formation of undesired bonds and side-reactions.1,2 Thus a promising synthetic strategy can be 
jeopardized if the corresponding protecting groups are not properly chosen.   
Emil Fischer was possibly the first to recognize the need to temporally mask a functional 
group to allow regioselective bond formation in the synthesis of carbohydrates.3 However, the 
first “modern” protecting group was the benzylozycarbonyl (Z) developed by Bergmann and 
Zervas.4 Z fits with the main characteristics associated with a protecting group: (i) it is easily 
introduced into the functional group; (ii) it is stable to a broad range of reaction conditions; 
and (iii) it is safely removed at the end of the synthetic process or when the functional group 
requires manipulation.  Another cornerstone in this field was when Barany et al.5,6 described 
the concept of orthogonality, in the sense that the two or more protecting groups belong to 
independent classes and are removed by distinct mechanisms.  The groups can be removed 
therefore in any order and in the presence of the rest. Orthogonal protection schemes are 
usually milder because selective deprotection is governed by alternative cleavage mechanisms 
rather than by reaction rates.  Since the pioneernig work of Bergmann and Zervas, the 
development of new protecting groups has been deeply tied to peptide chemistry.  Protection 
is totally mandatory for the construction of these polyfunctional molecules, which contain up 
to eight distinct functional groups in addition to indole and imidazole rings, which should also 
be protected.  Only the carbonyl function is absent from the natural amino acids, because even 
phosphate-protecting groups have been developed for the synthesis of phosphopeptides.  
Thus, the protecting groups first developed for peptide synthesis have been rapidily adapted 
for the protection of building blocks used for the contruction of non-peptide molecules.1,2 
Herein, we provide a concise but deep analysis of the protection of amino acids.  The review 
is divided into sections depending on the amino acid funcionalities protected. For each case, 
methods for the introduction of the protecting groups as well as for their removal are 
discussed. In each section, protecting groups are classified based on the following criteria: (i) 
the most used in a Boc/Bn strategy; (ii) the most used in a Fmoc/tBu strategy; (iii) decreased 
order of lability; and (iv) the most recently described, for which, in most cases, their potential 
has not yet been explored.  In all cases, families of protecting groups are classified together. 
The compatibility of each protecting group with regard to the others is indicated in the 
column “Stability to the removal of”, which shows which of the following α-amino- 
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protecting groups (Boc, Fmoc, Z, Trt, Alloc and pNZ) can be removed without affecting a 
particular protector.  
Special attention has been given to new protecting groups described in 2000-2008.   Those 
described in the literature earlier and that not have found a broad use have been omitted from 
this review.  
 
2. α-AMINO  
2.1 General  
Protection of the α-amino functionality of amino acids is one of the most important issues in 
peptide chemistry and is mandatory to prevent polymerization of the amino acid once it is 
activated. 
As most peptide syntheses, both in solution and on solid phase, are carried out in the C to N 
direction, α-amino-protecting groups (temporary protecting groups) are removed several times 
during the synthesis and therefore removal must be done in mild conditions that do not affect 
the remaining protecting groups (permanent, usually removed in the last step of the synthetic 
process, and semi-permanent, usually at the C-terminus, removed in the presence of all other 
protecting groups, when the peptide is to be coupled at its C-terminus) or even the peptidic 
chain.  
The α-amino-protecting group should confer solubility in the most common solvents and 
prevent or minimize epimerization during the coupling, and its removal should be fast, 
efficient, free of side reactions and should render easily eliminated by-products.  Other 
desired characteristics of α-amino-protected amino acids are that they are crystalline solids, 
thereby facilitating manipulation, and stable enough. 
The most common α-amino-protecting groups for solid-phase peptide synthesis (SPPS) are 
the 9-fluorenylmethoxycarbonyl (Fmoc) and the tert-butyloxycarbonyl (Boc) groups, used in 
the Fmoc/tert-butyl (tBu) and Boc/benzyl (Bn) strategies respectively. 
For solution synthesis, other α-amino-protecting groups used are the Z, the Nps (2-
nitrophenylsulfenyl) and the Bpoc [2-(4-biphenyl)isopropoxycarbonyl] in combination with 
tBu-type side chain protection; or the Boc group in combination with Bn-type side chain 
protection. 
2.2. Introduction of the protecting groups 
As there are several types of α-amino-protecting groups, there is a wide range of protection 
methodologies. Most of these are based on the reaction of the free amino acids (side chain-
protected if necessary, see ω-amino protection part for selective Lys and Orn side chain 
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protection), with an haloformate7 or dicarbonate8,9 of the protecting group under Schotten 
Baumann conditions (use of  biphasic system: organic solvent-aqueous basic conditions) or 
with the corresponding halide in organic solvents.10 Nevertheless, in some cases the presence 
of the free α-carboxylic acid can interfere in the reaction and lead, for instance, to the 
formation of dipeptides (Figure 1).11,12 ,13,14,15,16,17,18   
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Figure 1.  Mechanism for the formation of protected dipeptides during the protection of 
amino acids with haloformates.  Adapted from 19.  
 
The methodologies used to overcome this problem can be divided into two types: those that 
involve a carboxylic acid-protecting group which is removed upon amino protection and those 
that involve less reactive electrophiles on the reagent used to introduce the protecting group. 
An example of the former is the use of trimethylsilyl esters of amino acids prepared in 
situ,18,20 while an illustration of the latter is the use of N-hydroxysuccinimido (HOSu) 
derivative or the corresponding azide, as in the case of the introduction of Fmoc where Fmoc-
OSu or Fmoc-N3 are used instead of Fmoc-Cl.  However, the use of Fmoc-OSu can lead to 
the formation of tiny amounts of Fmoc--Ala-OH or even of Fmoc--Ala-AA-OH (Figure 
2), which can jeopardize the preparation of Fmoc-amino acids for the production of peptide- 
based Active Pharmaceutical Ingredients (API).19,21 
 
Comentario [m1]: Refenecia Schotten 
Baumann 
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Figure 2.  Mechanism for the formation of Fmoc--Ala-OH and Fmoc--Ala-AA-OH during 
the protection of amino acids. Adapted from 19.  
 
2.3. Removal 
2.3.1.  Protecting groups removed by acid 
- tert-Butyloxycarbonyl (Boc).22,23 Boc-amino acids are generally crystalline solids and their 
particular suitability for SPPS has been clearly demonstrated.24,25 The Boc group has been 
used for the solid-phase synthesis  (SPS) of a number of relevant peptides using the so-called 
Boc/Bn strategy. The most common removal conditions for Boc are 25-50% TFA in DCM 
but other acids, such as 1 M trimethylsilyl chloride (TMS-Cl)-phenol in DCM,26 4 M HCl in 
dioxane and 2 M MeSO3H in dioxane,27 have been successfully used for solution and solid-
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phase synthetic strategies.  The Boc group is stable to bases and nucleophiles as well as to 
catalytic hydrogenation. 
- Trityl (Trt).28,29  It is removed with 1% TFA in DCM or 0.1M HOBt in 2,2,2-trifluoroethanol 
(TFE) in solution. It can be removed in ever milder conditions such as 0.2% TFA, 1% H2O in 
DCM30  or 3% trichloroacetic acid (TCA) in DCM,31 which are compatible with the TFA 
labile 3-(4-hydroxymethylphenoxy)propionic acid (AB) linker or even with the more acid 
labile Riniker handle,32 as well as with the synthesis of oligonucleotide-peptide conjugates. 
Coupling yields of Trt-amino acids are lower than those of carbamate-protected amino acids. 
An important application of the Trt group is for the protection of the second C-terminal amino 
acid in order to prevent diketopiperazines (DKP) formation in a similar way as for the Boc 
strategy.33,34 This procedure involves the coupling of the third amino acid with in situ 
neutralization after the removal of the Trt group.30  
Incorporation of Trt-amino acids is more difficult than that of carbamate-protected amino 
acids, which implies the use of more powerful activating conditions. However, the bulkiness 
of the Trt group protects the α-proton from the base abstraction and therefore makes Trt-AA-
OH more difficult to racemize.35 
- α,α-Dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz).36 Although Ddz is more acid-stable 
than the Bpoc and the Trt groups, its removal with 1-5% TFA in DCM makes it compatible 
with tBu-type side chain protection.,37  It can also be removed by photolysis at wavelengths 
above 280 nm,36 which makes it potentially very useful for SPS library screening procedures. 
It has been used to prevent DKP formation in the Backbone Amide Linker (BAL) strategy in 
a similar way as the Trt group.38 However, an advantage of Ddz- over Trt-amino acids is that 
their incorporation is easier, which is a crucial factor when the corresponding amino acids are 
to be incorporated on hindered amines.38 
- 2-(4-Biphenyl)isopropoxycarbonyl (Bpoc).39 It is a highly acid-sensitive carbamate-type 
protecting group, which is removed with 0.2-0.5% of TFA except when used in poly(ethylene 
glycol)-based resins, in which more TFA is required because some of the acid is used to 
protonate the oxymethyl moieties. 40 This is a common characteristic of several acid labile-
protecting groups.41 Most Bpoc-amino acids are oils and are unstable because the free α-
carboxylic acid is acidic enough to remove the Bpoc group. Thus, these amino acids are 
usually stored either as DCHA salts or as pentafluorophenyl esters.42  In the early stages of 
SPPS, before the introduction of Fmoc group, Bpoc-amino acids have been used in 
combination with tBu-type side chain protection.40  Currently, Bpoc-amino acids are used 
Comentario [m2]: Ref. BAL 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
 9
mostly for peptide derivatives containing phosphate groups such as phospopeptides or 
peptide-oligonucleotide conjugates.43,44 
- 2-Nitrophenylsulfenyl (Nps).45 It is removed most conveniently with diluted solutions of HCl 
in AcOH.46 It is resistant to bases but can be removed by nucleophiles such as 2-
mercaptopyridine in combination with AcOH in MeOH, DMF or DCM.47 Removal using a Ni 
Raney column and organic solvents, such as DMF, has also been described. 48  Nps has been 
applied in both solution and SPS. Its high acid lability requires similar precautions to the 
Bpoc group in the presence of the free α-carboxylic acid. 
- Benzyloxycarbonyl (Z). See “other protecting groups” 
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Name and Structure 
 
Removal conditions 
Stability to 
the removal 
of 
 
Ref. 
tert-Butyloxycarbonyl (Boc) 
 
1) 25-50% TFA-DCM 
2) 4 M HCl in dioxane 
3) 2 M MeSO3H in 
dioxane 
4) 1M TMS-Cl, 1M 
phenol-DCM 
Fmoc, Z,a 
Trt, Alloc, 
pNZ 
22,23, 
24,25, 
26,27 
Trityl (Trt) 
 
1) 1% TFA-DCM  
2) 0.1M HOBt-TFE 
3) 0.2% TFA, 1% H2O- 
DCM  
4) 3% TCA-DCM 
Fmoc, Alloc 28,29, 
30,31, 
33,35 
3,5-dimethoxyphenylisoproxycarbonyl 
(Ddz) 
O
O
O
O  
1-5% TFA-DCM Fmoc, Alloc 36,37, 
38 
2-(4-Biphenyl)isopropoxycarbonyl 
(Bpoc) 
O
O  
0.2-0.5%-TFA  Fmoc, Alloc 39,40, 
41,42, 
43,44 
2-Nitrophenylsulfenyl (Nps) 
 
S
NO2  
1) Diluted solutions of 
HCl-CHCl3-AcOH 
2) 2-Mercaptopyridine-
AcOH-MeOH, DMF or 
DCM 
3) Ni Raney column in 
DMF 
Fmoc 45,46, 
47,48 
 a Catalytical hydrogenation removal. 
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2.3.2. Protecting groups removed by base 
- 9-Fluorenylmethoxycarbonyl (Fmoc).49,50  It is removed by bases (mainly secondary 
amines, because they are better at capturing the dibenzofulvene generated during the 
removal), and is stable to acids. It is not completely stable to the catalytic 
hydrogenolysis treatment required to remove benzyl esters when Pd/C or PtO2 are used 
as catalysts The most selective catalyst is Pd/BaSO4.51 Solution removal: liquid NH3 (10 
h) and morpholine or piperidine (within minutes), 10% diethylamine (DEA), 
dimethylacetamide (DMA) (2 h),52 polymeric (silica gel or polystyrene) secondary 
amines (i.e. piperazine, piperidine) in organic solvents.53,54 Applied for the first time for 
SPPS by two different laboratories independently.55,56 Since then, several optimized 
removal conditions for SPS have been described, the most relevant being: 20% 
piperidine in DMF,55 which is the most common, 1-5% DBU in DMF,57,58 morpholine-
DMF (1:1)59 or  2% HOBt, 2% hexamethyleneimine, 25% N-methylpyrrolidine in 
DMSO-NMP (1:1),60 the latter method leaving thioesters intact. The addition of a 
relatively small amount of HOBt to the piperidine solution [0.1 M HOBt in piperidine-
DMF (2:8)] reduces the formation of aspartimide in the sequences prone to this side 
reaction.61,62  
Fmoc α-amino protection has been used for the SPS of several relevant peptides using 
the so-called Fmoc/tBu strategy, the production in Tm scale of the T20 peptide being 
one of the most important examples.63  Nevertheless, the low solubility of some Fmoc 
derivatives in the most commonly used solvents for SPPS has stimulated the search for 
new base-labile protecting groups. 
- 2-(4-Nitrophenylsulfonyl)ethoxycarbonyl (Nsc).64 It is considered the most promising 
alternative to the Fmoc group.65,66,67,68 Nsc-amino acids are crystalline solids, more 
soluble in common solvents than Fmoc amino acids, and can be deprotected with 20% 
of piperidine or 1% DBU in DMF or preferably in DMF-dioxane (1:1).64,66 
Nevertheless, the use of DBU accelerates aspartimide formation and other side 
reactions.69 Nsc is 3-10 times more base-stable than the Fmoc group,66 thereby 
preventing its undesired removal under slightly basic conditions. This is particularly 
relevant in the synthesis of polyproline peptides in which the use of the Fmoc group 
leads to deletions caused by premature Fmoc removal by the secondary amine of Pro 
whereas no Pro insertions are observed when Nsc is used,67 Nsc is also important in 
automated SPS, where amino acid solutions are stored for a long time. Further 
advantages of the Nsc vs. Fmoc group are that the formation of the olefin-amine adduct 
Comentario [a3]:  Chan, Weng C.; 
White, Peter D Editor(s). In Fmoc Solid 
Phase Peptide Synthesis  (2000),     
137-181.  Oxford University Press,  
Oxford, UK   
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after removal is irreversible and faster for Nsc66 and Nsc protection reduces 
racemization compared to Fmoc protection,67 which is particularly important in C-
terminal Ser, Cys and His. 
- 1,1-Dioxobenzo[b]thiophene-2-ylmethyloxycarbonyl (Bsmoc).70 It is the most 
important of a series of protecting groups that are removed via a Michael addition. 
Other protecting groups from the same family are the Bspoc (2-tert-butylsulfonyl-2-
propenoxycarbonyl)71 and the Mspoc (2-methylsulfonyl-3-phenyl-1-prop-2-
enyloxycarbonyl)72  and the Mspoc groups. The Michael addition removal mechanism 
has several advantages over the β-elimination removal mechanism of Fmoc and Nsc: (i) 
back alkylation by the β-elimination by-product is prevented because the deblocking 
event is also a scavenging event;70 (ii) base-catalyzed side reactions, such as aspartimide 
formation, are minimized as a result of lower concentrations of secondary amines 70,73 
and (iii) the method can be applied to the rapid continuous solution synthesis technique. 
73,74 Bsmoc-amino acids have been used to synthesize several model peptides in which 
the Bsmoc group was removed with 2-5 % piperidine in DMF,70 and have shown better 
performance than Fmoc amino acids in difficult couplings such as Aib-Aib.41 
Furthermore, the Bsmoc group can be selectively removed with 2% of tris(2-
aminoethyl)amine (TAEA) in DCM in the presence of Fm esters.70  
- (1,1-Dioxonaphtho[1,2-b]thiophene-2-yl)methyloxycarbonyl (α-Nsmoc).75 It is a novel 
alternative to the Bsmoc group and is removed in the same way but slightly faster. α-
Nsmoc-amino acids are crystalline solids, thus they are a good alternative to Bsmoc in 
the cases where Bsmoc-amino acids are oils. 
- (1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-ethyl) (Dde) and 1-(4,4-Dimethyl-
2,6-dioxocyclohex-1-ylidene)-3-mehtylbutyl (ivDde). Both groups are removed by 
hydranzinolysis and although can be used for α-amino protection,76 their principal 
application is for the protection of Lys and Orn side chains. See Lys and Orn protection. 
- 2,7-Di-tert-butyl-Fmoc (Fmoc*).77 It is removed in the same conditions as the Fmoc 
group but is up to four times slower.  Fmoc*-amino acid derivatives are more soluble 
than the Fmoc ones.77,78 They have been recently used for the synthesis of cyclic 
modular β-sheets.79 
- 2-Fluoro-Fmoc (Fmoc(2F)).80 It is a more base-labile derivative of the Fmoc group 
and has been used for the SPS of phosphopeptide thioesters. It is removed with a 4-min 
treatment with 4% HOBt in 1-methylpyrrolidine-hexamethylenimine-NMP(1-
methylpyrrolidin-2-one)-DMSO (25:2:50:50).  
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- 2-Monoisooctyl-Fmoc (mio-Fmoc) and 2,7-Diisooctyl-Fmoc (dio-Fmoc).81 Both are 
novel protecting groups reported to show greater solubility than Fmoc* derivatives in 
DCM-MeOH (100:4). Their removal with 20% piperidine in DMF is slower than Fmoc 
removal; 2 times slower in the case of mio-Fmoc and 5 times slower for dio-Fmoc. 
- Tetrachlorophthaloyl (TCP).82 It is a relatively new protecting group proposed for 
SPPS. It is removed with hydrazine in DMF (15% of hydrazine, at 40 °C, 1 h for 
repetitive deprotection) but stable to piperidine and to Boc removal conditions. It is also 
used for side chain amino protection. 
- 2-[Phenyl(methyl)sulfonio]ethyloxycarbonyl tetrafluoroborate (Pms).83 Pms-amino 
acids are water-soluble. They have been developed relatively recently and allow SPPS 
in water. Pms is removed with 5% aqueous NaHCO3, 2 x 3 min and 1 x 30 min for 
SPS.83,84 Nevertheless, since Pms is an onium salt it is rather unstable compared to 
conventional protecting groups.85 
- Ethanesulfonylethoxycarbonyl (Esc).85 It is another relatively new protecting group for 
peptide synthesis in water. The deriavatives of Esc are more stable than those of Pms. It 
is removed either by 0.025 M NaOH in H2O-EtOH (1:1) or 0.05 M TBAF in DMF.  
- 2-(4-Sulfophenylsulfonyl)ethoxycarbonyl (Sps).86 Developed parallelly to Esc at almost 
the same time, it is also a protecting group for SPS in water. It is removed with 5% 
aqueous Na2CO3. Sps-amino acids have a similar stability to Esc ones but with the 
advantage that they absorb in the UV. 
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Name and Structure Removal conditions Stability to 
the 
removal of 
Ref. 
9-Fluorenylmethoxycarbonyl (Fmoc) 
 
 
 
O
O
 
Solid phase: 
1) 20% piperidine-DMF 
2) 1-5% DBU-DMF  
3) morpholine-DMF 
(1:1)  
4) 2% HOBt, 2% 
hexamethyleneimine, 
25% N-methylpyrrolidine 
in DMSO-NMP (1:1) 
Solution: 
1) NH3 (10 h)  
2) morpholine or  
piperidine in organic 
solvents (within minutes) 
3) 10% DEA,DMA (2 h) 
4) polymeric secondary 
amines (i.e. piperidine, 
piperazines) in organic 
solvents 
 Boc, Z,a 
Trt, Alloc,  
pNZ a 
49,50, 
51,52, 
53,54, 
55,56, 
57,58, 
59,60, 
61,62 
2-(4-Nitrophenylsulfonyl)ethoxycarbonyl 
(Nsc) 
O2N S
O O
O
O
 
1) 20% of piperidine-
DMF or DMF-dioxane 
(1:1) 
2) 1%  DBU-DMF or 
DMF-dioxane (1:1) 
Boc, Trt, 
Alloc 
64,65, 
66,67, 
68,69 
1,1-Dioxobenzo[b]thiophene-2-
ylmethyloxycarbonyl (Bsmoc) 
SO2 O
O  
1) 2-5% piperidine-DMF 
2) 2% TAEA-DCM 
Boc, Trt, 
Alloc 
70,71, 
72,73, 
74 
(1,1-Dioxonaphtho[1,2-b]thiophene-2-
yl)methyloxycarbonyl (α-Nsmoc) 
SO2 O
O
 
1) 2-5% piperidine-DMF 
2) 2% TAEA-DCM 
Boc, Trt, 
Alloc 
75 
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1-(4,4-Dimethyl-2,6-dioxocyclohex-1-
ylidene)-3-methylbutyl  (ivDde) 
OO
 
2% N2H4·H2O-DMF 
 
Boc, Fmoc, 
Z,a Trt, 
Alloc 
 
2,7-Di-tert-butyl-Fmoc (Fmoc*) 
tBu
tBu
O
O
 
20% piperidine,DMF 
(solid phase) 
 
Boc, Trt, 
Alloc 
 
77,78, 
79 
2-Fluoro-Fmoc (Fmoc(2F)) 
O
O
F
 
4% HOBt- 
1-methylpyrrolidine-
hexamethylenimine-
NMP-DMSO 
(25:2:50:50), 4 min. 
Boc, Trt, 
Alloc 
 
80 
2-Monoisooctyl-Fmoc (mio-Fmoc) and 2,7-
Diisooctyl-Fmoc (dio-Fmoc) 
 
20% piperidine-DMF  81 
Tetrachlorophthaloyl (TCP) 
O
O
Cl
Cl
Cl
Cl  
15% hydrazine-DMF, 1 
h, 40ºC 
Boc, Fmoc, 
Trt 
82 
2-Phenyl(methyl)sulfonio)ethyloxycarbonyl 
tetrafluoroborate (Pms) 
S O
O
 
5% NaHCO3 (aq) Boc, Trt  83,84, 
85 
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Ethanesulfonylethoxycarbonyl (Esc) 
S
O O
O
O  
0.025 M NaOH-H2O-
EtOH (1:1) 
Boc, Trt  85 
2-(4-sulfophenylsulfonyl)ethoxycarbonyl 
(Sps) 
S O
O
HO3S
O O
 
5%  Na2CO3 (aq) Boc, Trt  86 
a Except catalytical hydrogenation removal. 
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2.3.3. Other protecting groups 
- Benzyloxycarbonyl (Z).4  It is one of the most widely used α-amino-protecting groups 
for peptide synthesis in solution because of: (i) the easy preparation of Z-protected 
amino acids; (ii) the high stability of protected amino acids and peptides, which are 
stable to base and mild acid treatments (stability to Boc removal); (iii) the versatile 
removal conditions: by catalytical hydrogenolysis during chain elongation or by strong 
acids (HBr in acetic acid,87 TFA at high temperatures,88 TFA-thioanisole,89 liquid HF,90 
BBr3)91 in the final deprotection of  the peptide; and (iv) the supression of racemization 
during peptide bond formation.92  
- Allyloxycarbonyl (Alloc).93,94,95,96,97 It is removed by a palladium-catalyzed (usually 
Pd(PPh3)4) transfer of the allyl unit to various nucleophiles/scavengers (preferably: 
H3N·BH3, Me2NH·BH3 or PhSiH3)98,99 in the presence of a proton source. The use of 
scavengers is mandatory to prevent allylation of the free amine upon Alloc removal. If 
removed on solid phase, washings with sodium N,N-diethyldithiocarbamate (0.02 M in 
DMF, 3 x 15 min) are carried out in order to remove Pd. Alloc-amino acids are oils but 
can be stored as DCHA salts or pentafluorophenyl esters, both of which are crystalline 
solids.100 The use of Alloc group is compatible with the Boc/Bn and Fmoc/tBu strategies 
and allows tandem removal-acylation reactions when the palladium-catalyzed amino 
deblocking is performed in the presence of acylating agents.101 This strategy has been 
used to prevent DKP formation.102 Alloc has recently been applied as α-amino-
protecting group for a convergent synthesis of the anti-tumoral peptide Kahalalide F.103 
- o-Nitrobenzenesulfonyl (oNBS) and p-nitrobenzenesulfonyl (pNBS).104 The most used 
is oNBS. It is removed by a nucleophilic aromatic substitution mechanism using β-
mercaptoethanol and DBU when it is protecting N-alkyl derivatives but the deblcoking 
of primary amines fails under these conditions and the cocktail used is 5% thiophenol in 
DMF containing 2 eq. of K2CO3.  The main advantage of oNBS- vs Fmoc-amino acids is 
that the former do not form oxazolones and thus oNBS-amino acyl chlorides can be 
used in difficult couplings with less risk of racemization.105  oNBS α-amino-protection 
is also used for site-specific alkylation of amino acids on solid phase,106,107 making 
these groups unique for the preparation of N-Me peptides (Figure 3).   
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Figure 3.  oNBS protection for the synthesis of N-alkyl peptides. Reprinted with 
permission from ref. 106 and 107. Copyright 1997, 2005, American Chemical Society. 
 
- 2,4-Dinitrobenzenesulfonyl (dNBS).108 It is removed by treatment with HSCH2CO2H 
(1.2 eq.) and TEA (3 eq.) in DCM for 30 min, leaving oNBS unaltered.  
- Benzothiazole-2-sulfonyl (Bts).105,109   Used in solution in a similar way to NBS 
groups. It is removed using thiophenol and base (K2CO3, DIPEA or tBuOK) in both 
primary and secondary amines, NaBH4 in EtOH41 or HS(CH2)2CO2H, Na2CO3 in 
DMF110 for secondary amines, and other reducing agents, such as Zn, H3PO2, Al/Hg, 105 
which can be used for primary and secondary amines. However, in the latter case the 
reaction is slower and highly concentration-dependent. Bts has been used for the 
synthesis of the cyclosporin 8-11 tetrapeptide subunit, which contains three N-
methylamino acids,109 and more recently for the synthesis of macrocyclic antagonists of 
the Human Motilin Receptor.111 
- 2-Nitrophenylsulfanyl (Nps): See protecting groups removed by acid. 
- 2,2,2-Trichloroethyloxycarbonyl (Troc).112 It is a classical protecting group that can be 
removed selectively in the presence of Z, Boc, Fmoc and Alloc groups via a Grob 
fragmentation using Zn dust in 90% aqueous AcOH or other reducing agents.112,113 It is 
not stable to catalytic hydrogenolysis. 
- Dithiasuccinoyl (Dts).114 It is removed with mild thiolysis using 0.5 M β-
mercaptoethanol and 0.5 M DIPEA in DCM or 0.5 M N-methyl mercaptoacetamide 
(NMM) in DCM.115 It was used for α-amino protection in the first three-dimensional 
orthogonal protection scheme suitable for the preparation of fully and partially protected 
peptides, which also involved tert-butyl type groups for side chain protection and an o-
nitrobenzyl ester linkage.6 Although Dts is not commonly used for the synthesis of 
peptides, it has proved useful for the synthesis of peptide nucleic acids (PNA)116 and O-
glycopeptides by protecting the 2-amino substituent in the corresponding glycosyl 
donors.117  
- p-Nitrobenzyloxycarbonyl (pNZ).118 It is a classical protecting group which has 
recently found further applicability for the synthesis of complex peptides as well as for 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
 19
minimizing side-reactions.119 It is much more stable to strong acids than the Z group 
and is removed by reduction with tin(II) chloride in nearly neutral conditions (1.6 mM 
HCl(dioxane)) in solid-phase and in solution synthesis,119,103 as well as by catalytic 
hydrogenolysis or Na2S2O4 120 for solution synthesis. pNZ is orthogonal to the three 
most important amino-protecting groups, Boc, Fmoc, and Alloc, thereby making it 
highly suitable for the synthesis of cyclic complex peptides such as oxathiocoraline.121 
If the second C-terminal amino acid in SPPS is introduced as pNZ derivative and the 
pNZ group is removed using SnCl2 and catalytic ammounts of HCl, the formation of 
DKP is prevented. The formation of aspartimides is also prevented using pNZ-amino 
acids from the Asp residue to the N-terminus.119  
- α-Azido carboxylic acids.122,123 Although not widely used because of the instability of 
azides, there are examples of their successful application in SPPS.124,125 The azide is 
reduced to amine using trimethylphospine in dioxane. α-Azido carboxylic acids can be 
coupled as acyl chlorides without oxazolone formation.  
- Propargyloxycarbonyl (Poc).126,127   It is removed by ultrasonic irradiation in the 
presence of  tetrathiomolybdate complexes such as [(PhCH2NEt3)2MoS4] in AcCN. It is 
a relatively new and still not widely used protecting group for solution-phase peptide 
synthesis. It is stable to Boc removal conditions and has been used to protect amino acid 
chlorides to be used in couplings on hindered amines without racemization.  
- o-Nitrobenzyloxycarbonyl (oNZ) and  6-Nitroveratryloxycarbonyl (NVOC).128 They 
are removed by photolysis at wavelengths greater than 320 nm in the presence of 
additives such as N2H4, NH2OH·HCl, or semicarbazide hydrochloride for several hours, 
oNZ being the most easily removed. NVOC has been used for combinatorial library 
production using the Affymax methodology.129 Research effort is being made to 
develop more easily removable photolabile protecting groups. 
- 2-(2-Nitrophenyl)propyloxycarbonyl (NPPOC).130 It is a photolabile amino-protecting 
group that is removed by UV light (λ=365 nm) about twice as fast as the classical 
NVOC group.  
- 2-(3,4-Methylenedioxy-6-nitrophenyl)propyloxycarbonyl (MNPPOC).131 It is removed 
faster than the NPPOC and has been developed recently by the same research group. 
- Ninhydrin (Nin). See Cys protection. 
- 9-(4-Bromophenyl)-9-fluorenyl (BrPhF).132 It is a recently proposed safety-catch 
amino-protecting group and has been tested only for solution synthesis. It prevents 
epimerization and is more acid stable than the Trt group due to the the anti-aromatic 
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nature of the fluorenyl group. tBu esters can be selectively cleaved in its presence by 
using ZnBr2 in DCM or trichloroacetic acid.133,132 BrPhF is removed by Pd-catalyzed 
aminolysis with morpholine, followed by treatment of the resulting acid-labile 
morpholine adduct with DCA and triethylsilane (TES) in DCM.  
- Azidomethyloxycarbonyl (Azoc).134 It is a novel protecting group proposed for 
solution- and solid-phase synthesis. It is removed by reduction of the azide with 
phosphines. The removal is rapid when PMe3 or PBu3 (5 min on solid phase) are used, 
and slower with polymer-bound PPh3  (30 min). Azoc is orthogonal to Fmoc and Mtt.  
- Bidentate protecting groups.135Another possibility is the use of bidentate reagents such 
as N-carboxy anhydrides (NCA) and the oxazolidinones derived from 
hexafluoroacetone (HFA) or formaldehyde, which undergo heterocyclization with the 
amino and the α-carboxylic group. In the heterocycle, the carboxylic group is 
electrophilic, and a carboxy-derivatization is accompanied by N-deprotection (Figure 4). 
 
N
O
R
O
F3C
CF3
Nu
H2N F3C CF3
OO
Nu
R
 
Figure 4. Deprotection of a HFA-protected amino acid via nucleophilic attack 
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Name and Structure Removal conditions Stability to 
the removal 
of 
Ref. 
Benzyloxycarbonyl (Z) 
O
O
 
 
1) H2 cat 
2) Strong acids such as: 
HBr in AcOH, TFA at 
high temperatures, TFA-
thioanisole or liquid HF 
3) BBr3 
Boc, Fmoc, 
Trt, Alloc, 
pNZ a 
 
4,87,88,89, 
90,91,92 
Allyloxycarbonyl (Alloc) 
O
O  
Pd(PPh)3 cat., scavengers: 
H3N·BH3, Me2NH·BH3 or 
PhSiH3 in organic solvents 
Boc, Fmoc, 
Trt, pNZ a 
93,94,95, 
96,97,98, 
99,100,101, 
102,103 
o-Nitrobenzenesulfonyl 
(oNBS) 
S
NO2
O
O
 
1) 5% thiophenol-DMF, 2 
eq. of K2CO3 (primary 
amines) 
2) β-mercaptoethanol and 
DBU (secondary amines) 
Boc, Fmoc, 
Trt 
104,105, 
106,107 
2,4-Dinitrobenzenesulfonyl 
(dNBS) 
S
NO2
O
O
O2N
 
HSCH2CO2H (1.2 eq.), 
TEA (3 eq.) in DCM  
Boc, Trt 108 
Benzothiazole-2-sulfonyl (Bts) 
S
N
S
O
O  
1) Al/Hg 
2) Zn 
3) H3PO2 
4) PhSH and base (K2CO3, 
DIPEA, potassium tert-
butoxyde) 
5) NaBH4 in EtOH  
- 41,105,109, 
110,111 
2,2,2-
Trichloroethyloxycarbonyl 
(Troc) 
Cl3C O
O
 
Zn in 90% AcOH(aq) Boc, Fmoc, 
Trt 
112,113 
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Dithiasuccinoyl (Dts) 
 
1) 0.5 M β-
mercaptoethanol and 0.5 
M DIPEA-DCM  
2) 0.5 M N-
methylmercaptoacetamide-
NMM-DCM  
Boc, Trt 6,114,115, 
116,117 
p-Nitrobenzyloxycarbonyl  
(pNZ)  
O
O
O2N  
1) 1-6 M SnCl2, 1.6 mM 
HCl(dioxane) in DMF 
2) H2 cat 
Boc, Fmoc, 
Trt, Alloc  
103,118,119, 
120,121 
α-Azidoacids 
N3 COOH
R  
PMe3 in dioxane - 122,123,124, 
125 
Propargyloxycarbonyl (Poc) 
O
O
 
[(PhCH2NEt3)2MoS4] in 
AcCN (ultrasonic 
irradiation) 
Boc 126,127 
o-Nitrobenzyloxycarbonyl  
(oNZ)  
O
ONO2
 
photolysis (λ>320 nm), 
additives:N2H4, 
NH2OH·HCl, or 
semicarbazide·HCl  
(several hours) 
Boc, Fmoc, 
Trt, Alloc 
128 
4-Nitroveratryloxycarbonyl 
(NVOC) 
O
ONO2
MeO
OMe  
photolysis (λ>320 nm), 
additives: N2H4, 
NH2OH·HCl, or 
semicarbazide·HCl 
(several hours) 
Boc, Fmoc, 
Trt, Alloc 
128,129 
2-(2-
Nitrophenyl)propyloxycarbonyl 
(NPPOC) 
O
NO2
O  
photolysis (λ=365 nm), 
additives: 2.5 mM 
semicarbazide·HCl in 
MeOH 
 
Boc, Fmoc, 
Trt, Alloc 
130 
2-(3, 4-Methylenedioxy-6-
nitrophenyl) 
propyloxycarbonyl (MNPPOC) 
O
NO2
O
O O
 
photolysis ((λ>350 nm)) 
 
Boc, Fmoc, 
Trt, Alloc 
131 
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9-(4-Bromophenyl)-9-
fluorenyl (BrPhF) 
Br
 
i) 2.5 mmol Pd(OAc)2 (0.05 
eq.), BINAP (0.05 eq.), dry 
Cs2CO3 (5 eq.), 
 morpholine (1.2 eq.) in 
toluene at reflux, 24 h. 
 (ii)  DCA-TES-DCM 
(14:3:83), 30 min. 
- 132,133 
Azidomethyloxycarbonyl 
(Azoc) 
N3 O
O
 
1) 1M PMe3 in THF-H2O 
(9:1), 2-5 min. 
2) 1M PBu3 in THF-H2O 
(9:1), 2-5 min. 
3) Polymer-bound PPh3 (20 
eq.) in  THF-H2O (9:1), 30 
min. 
Fmoc  134 
Hexafluoroacetone (HFA) 
 
Nucleophiles (i.e. alcohols, 
amines, H2O) 
Boc, Trt, 
Allocb 
135 
a Except catalytical hydrogenation removal. 
b Using PhSiH3 as scavenger. 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
 24
3. LYSINE (Lys), ORNITHINE (Orn), DIAMINOPROPIONIC ACID (Dap) AND 
DIAMINOBUTYRIC ACID (Dab) 
3.1. General  
The protection of the side chains of lysine (Lys) and ornithine (Orn) as well as 
diaminopropionc acid (Dap) and diaminobutyric acid (Dab) (Figure 5) is essential in 
peptide synthesis to prevent their acylation, which would lead to the formation of 
undesired branched peptides.  
 
  
Figure 5. Diaminopropionic acid (Dap), Diaminobutyric acid (Dab), Ornithine (Orn), 
and Lysine (Lys) 
 
Several groups used for the α-amino funcionality have found application for amino side 
chain protection. It is worth commenting that ω-amino protection is more difficult to 
remove than α-amino protection because of the higher basicity of the former. Thus, for 
instance, in the case of trityl-type protection of the α-amino, the Trt group is used, 
whereas for the ω-amino the more electron-rich 4-methyltrityl (Mtt) is preferred. 
The most used permanent protecting groups for Orn and Lys side chains are the 2-
chlorobenzyloxycarbonyl (Cl-Z) and Z groups in the Boc/Bn strategy, and the Boc 
group in the Fmoc/tBu strategy. In the synthesis of branched or cyclic peptides there are 
several protecting groups orthogonal to Boc and Fmoc, Alloc being among the most 
popular. 
The N-Fmoc protecting group can be prematurely removed by a primary amine of 
sufficient basicity, such as the -amino group of Lys and to a lesser  extent the -amino 
of Orn and the -amino of Dab, present in the peptide.136,137 This side-reaction is not 
promoted by either the -amino side chain of the Dap residue or the -amino group. 
These results are consistent with the pKa values of these amino functions in the model 
compounds shown in Table 1. Thus, while the pKa values of the side amino functions of 
Lys, Orn, and Dab are very close, the pKa of Dap is lower by one unit, making this 
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amino function less basic than the other derivatives. The same explanation applies for 
the -amino function. 
 
Table 1.  pKa of amino function according to the pKalc module (PALLAS version 2.0, 
CompuDrug).   
H2N
O
NH2
NHO
O  
 
H
N
H2N
O
NH2
O
O
 
 
H
N
NH2
O
NH2
O
O
 
 
H
N
H2N
O
NH2
O
O
 
H
N
O
NH2
O
O
NH2  
pKa: 8.04 pKa: 8.49 pKa: 9.45 pKa: 10.00 pKa: 10.09 
 
These pKa values must be taken into consideration when the -amino-protecting group 
of Lys, Orn, or Dab is removed in the presence of an -amino protected by the Fmoc 
group.  An alternative is a  change of strategy, e.g. use of Alloc or Mtt for -amino and 
Fmoc for -amino protection, use of Mtt for -amino protection and a 
coupling/neutralization protocol similar to that used to prevent DKP formation after Mtt 
removal, or use of Alloc and a tandem deprotection-coupling reaction.136   
 3.2. Introduction of the protecting groups 
For blocking the -amino function, a safe method is copper (II) complexation where 
CuSO4·5H2O acts as a complexating agent with the α-amino and α-carboxylate groups, 
thereby allowing the selective protection of the ω-amino funcionality.138,139,140 Another 
alternative also based on complexation is the formation of boron complexes using 
B(Et)3 as the complexating agent.141 
In some cases (e.g: Z), side chain protection can be achieved by protecting both the α-
amino and the ω-amino funcionalities and then selectively deprotecting the former, 
taking advantage of their higher lability.142 
3.3. Removal 
3.3.1. Protecting groups removed by acid 
-2-Chlorobenzyloxycarbonyl (Cl-Z). It is removed with HF or TFMSA and is 
preferentially used in the Boc/Bzl solid phase strategy over the Z group because Cl-Z 
shows major resistance to the repetitive TFA treatments to remove Boc group.143  Both, 
Z and Cl-Z, are stable to bases and can be removed by hydrogenolysis in solution.  
- tert-Butyloxycarbonyl (Boc). It is removed with 25-50% TFA.144 It is used in the 
Fmoc/tBu solid phase strategy and is resistant to bases and catalytic hydrogenation. 
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- 4-Methyltrityl (Mtt). It can be used for temporary side chain protection in the Fmoc 
strategy and is a better option than Boc in the presence of sensitive amino acids such as 
Tyr, Met and Trp because it prevents side reactions during TFA cleavage because of the 
low electrophilicity of the bulky trityl cation. As expected, ω-amino protection with Trt-
type groups is more stable than α-amino protection. Removal of Mtt (4-methyltrityl) is 
performed selectively in the presence of Boc using 1% TFA in DCM for 30 min or with 
AcOH-TFE-DCM (1:2:7) for 1 h.145 More acid-labile derivatives, like 
monomethoxytrityl (Mmt) and dimethoxytrityl (Dmt), are more convenient when 
hydrophilic resins (e.g. TentaGel) are used.146   
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Name and Structure Removal 
conditions 
Stability to the 
removal of 
Ref. 
2-Chlorobenzyloxycarbonyl (Cl-Z) 
O
O
Cl  
1) HF, scavengers 
2) TFMSA-TFA 
3) H2 cat. 
 
Boc, Fmoc, Trt, 
Alloc, pNZ a 
 
143 
tert-Butyloxycarbonyl (Boc) 
O
O  
25-50% TFA-DCM Fmoc, Z,b Trt, 
Alloc, pNZ 
 
144 
4-Methyltrityl (Mtt) 
 
1) 1% TFA-DCM  
2) AcOH-TFE-
DCM (1:2:7) 
Fmoc, Alloc 145,146   
a Except catalytical hydrogenation removal. 
b Catalytical hydrogenation removal. 
 
3.3.2. Protecting groups removed by base 
- 9-Fluorenylmethoxycarbonyl (Fmoc).141 See also α-amino section. It is usually 
removed with 20% of piperidine in DMF or 1-5% DBU in DMF, its stability to acids 
makes it useful for the synthesis of cyclic and branched peptides using the Boc/Bn 
strategy. It is not completely stable to catalytic hydrogenation.   
- 1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-mehtylbutyl (ivDde).147 It is useful as 
a temporary protecting group in the synthesis of cyclic and branched peptides.148 ivDde 
is an improved derivative of Dde (1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-
ethyl),149,150,151 which is considerably less base-labile and therefore stable to Fmoc 
removal conditions and can be removed by hydrazinolysis. An additional advantage of 
ivDde is that its steric hindrance makes it is less prone to migrate to free Lys or Orn side 
chains (Figure 6).147 To prevent the reduction of the allyl group by hydrazine, allyl 
alcohol should be used when ivDde is removed in the presence of allyl-type protecting 
groups.152 
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Figure 6. Dde N→N’ migration. This side reaction is prevented using ivDde. 
 
- Trifluoroacetyl (tfa). 153  It is removed by alkali treatment (0.2 N NaOH in 10 min), 154 
aqueous piperidine 155,156,157 or sodium borhydride.158 It is stable to strong acids and 
therefore compatible with the Boc strategy. The basic conditions used for its removal 
may promote aspartimide formation if aspartic residues are present or pyroglutamyl 
formation in the case of  N-terminal glutamine residues.  
- 2-(Methylsulfonyl)ethoxycarbonyl (Msc).159 It is removed with 0.025-0.5 M Ba(OH)2, 
or the 4N NaOH(aq)-dioxane-MeOH (0.25:7.5:0.25). It is highly stable to acids (TFA rt 
and long reaction times, HF 0 ºC 30 min, HCl conc 40ºC 1h) 160 and hydrogenolysis. 
This reactivity allowed the use of ω-protection with Msc in combination with Boc and Z 
α-protection. 161 
- Tetrachlorophthaloyl (TCP).162  It is a relatively new protecting group proposed for 
SPPS and also used for α-amino protection. TCP side chain protection is removed with 
ethylenediamine-DMF (1:200) at 40°C, 1h in repetitive deprotections. Nevertheless, 
hydrazine-based removal used for α-amino deprotection leads to a complex mixture of 
compounds.162 TCP is stable to Fmoc, Boc and Alloc removal conditions. 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
 29
 
Name and Structure Removal 
conditions 
Stability to 
the 
removal of 
Ref. 
9-Fluorenylmethoxycarbonyl (Fmoc ) 
O
O
 
1) 20% piperidine-
DMF  
2) 1-5% DBU-DMF   
(See also α-amino ) 
Boc, Z,a Trt 
Alloc, 
pNZa 
141 
1-(4,4-Dimethyl-2,6-dioxocyclohex-1-
ylidene)-3-methylbutyl  (ivDde) 
OO
 
2% N2H4·H2O-DMF 
 
Boc, Fmoc, 
Z,a Trt, 
Alloc 
147,148,149, 
150,151,152 
Trifluoroacetyl  (tfa) 
F3C
O
 
1) 0.2N NaOH(aq)  
2) 1 M piperidine(aq) 
3) NaBH4 in EtOH 
Boc, Z,a 
Trt, Alloc 
153,154,155, 
156,157,158 
 
2-(Methylsulfonyl)ethoxycarbonyl 
(Msc)  
 
1) 0.025-0.5 M 
Ba(OH)2 
2) 4N NaOH(aq)-
dioxane-MeOH 
(0.25:7.5:0.25)  
Boc, Z,b  
Trt, Alloc 
159,160,161 
Tetrachlorophthaloyl (TCP) 
O
O
Cl
Cl
Cl
Cl  
Ethylenediamine-
DMF (1:200), 1 h, 
40ºC 
 
Boc, Fmoc, 
Trt, Alloc 
162 
a  Except catalytical hydrogenation removal. 
 b Catalytical hydrogenation removal. 
 
3.3.3. Other protecting groups 
- Allyloxycarbonyl (Alloc).163,164,102 It is removed using a palladium catalyst in the 
presence of a scavenger to capture the generated carbocation. It is compatible with the 
Boc/Bn and Fmoc/tBu strategies. See also α-amino protection. 
- 2-Chlorobenzyloxycarbonyl (Cl-Z). See protecting groups removed by acid. 
- p-Nitrobenzyloxycarbonyl (pNZ). See also α-amino protection section for removal 
details and references. pNZ protection of the side chains of  Lys and Orn prevents the 
undesired removal of the α-Fmoc group after side chain deprotection.165,166  
- 2-Nitrobenzyloxycarbonyl (oNZ). See α-amino protection. 
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- 6-Nitroveratryloxycarbonyl (NVOC).167  See α-amino protection. 
- Phenyldisulphanylethyloxycarbonyl (Phdec) and 2-Pyridyldisulphanylethyloxy- 
carbonyl (Pydec). These are recently developed protecting groups which have been used 
either for solution or solid-phase synthesis.168  Both are removed by mild thiolysis using 
dithiothreitol (DTT) or β-mercaptoethanol in Tris·HCl buffer (pH 8.5–9.0) for 
deprotection in water or by treatment with β–mercaptoethanol and DBU in NMP for 
deprotection in an organic medium.  
- o-Nitrobenzenesulfonyl (o-NBS). It is widely used for the α-N-methylation of amino 
acids. Because of its high stability to acids and bases, o-NBS has found application in 
the side chain protection of secondary amines derived from Lys and Orn. It is removed 
from secondary amines by mercaptoethanol in the presence of DBU.169,170 
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Name and Structure Removal conditions Stability 
to the 
removal 
of 
Ref. 
Allyloxycarbonyl (Alloc)  
O
O  
Pd(PPh)3 cat., 
scavengers: 
H3N·BH3, 
Me2NH·BH3 or 
PhSiH3 in organic  
solvents 
Boc, 
Fmoc, Trt, 
pNZ a 
102,163,164 
p-Nitrobenzyloxycarbonyl  
(pNZ)  
O
O
O2N  
1) 1-6 M SnCl2, 1.6 
mM HCl(dioxane)-DMF 
2) H2 cat 
3) Na2S2O4 
Boc, 
Fmoc, Z,a  
Trt, Alloc 
 165,166 
 
Phenyldisulphanylethyloxycarbonyl 
(Phdec)  
S
S
O
O  
1) DTT or β-
mercaptoethanol-
Tris·HCl buffer (pH 
8.5–9.0) 
2) β–
mercaptoethanol, 
DBU-NMP 
Boc, 
Fmoc, Trt 
168 
2-Pyridyldisulphanylethyloxycarbonyl 
(Pydec)  
N
S
S
O
O  
1) DTT or β-
mercaptoethanol-
Tris·HCl buffer (pH 
8.5–9.0) 
2) β–
mercaptoethanol, 
DBU-NMP 
Boc, 
Fmoc, Trt 
168 
o-Nitrobenzenesulfonyl 
(o-NBS) 
S
NO2
O
O
 
 β-mercaptoethanol, 
(5eq.) DBU (10 eq.)-
DMF 
Boc, 
Fmoc, Trt 
169,170 
a Except catalytical hydrogenation removal. 
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4. α-CARBOXYLIC ACID  
4.1. General 
The protection of the C-terminal carboxylic acid is different in SPS to in solution 
synthesis. In the former, the C-terminal is usually linked to the solid support and 
therefore the linker/handle acts as a protecting group. There are excellent reviews 
covering the linkers/handles used in SPPS and therefore they are out of the scope of the 
present review. Nevertheless, in some synthetic strategies where the peptide is linked to 
the resin by the backbone by an amino acid side chain, and also in the less frequent 
synthesis in the reverse N-C direction, 38,171,172 C-terminal protection is required. 
 In the case of solution synthesis, C-terminal protection is not needed to form the 
peptide bond. However, in other cases C-terminal protection is mandatory. 
4.2. Introduction of the protecting groups 173 
Protection of the α-carboxylic acid can be performed mainly by the following methods.  
- Reaction of a α-amino free amino acid with an alcohol in acidic conditions (HCl and 
p-TosOH are the most used acids).174 
- tert-Butyl protection by reaction of an α-amino free or protected amino acid with 
isobutene in acidic conditions (usually p-Tos-OH or H2SO4).175,176 
- Reaction of an α-amino-protected amino acid in the presence of base or as a cessium 
salt with the corresponding halide (usually bromide).177,178 
- Reaction of an α-amino-protected amino acid with a condensating agent such as DCC 
in the presence of DMAP and the alcohol derivative of the protecting group.179 
 
For the particular case of aspartic (Asp) and glutamic (Glu) acids α-carboxyl protection, 
two main strategies are possible: 
- Protection of the α-carboxylic acid after selective protection of the side chain of H-
Asp-OH or H-Glu-OH either via acid catalyzed esterification or in the presence of a 
copper chelate (see protection of side chain of Asp and Glu). Side chain deprotection 
renders the desired protected derivative.180,181,141  
- Selective protection of the α-carboxylic acid via formation of an intramolecular 
anhydride between the two carboxylic acids and reaction with the corresponding alcohol 
or via reaction with a halide in the presence of base. In both cases, N-protected Asp or 
Glu acid are used as starting materials. In the first case, selective α-protection is 
achieved as a result of the major electrophilicity of the α-carboxylic acid, whereas in the 
second the selective protection is due to the major acidity of the α-carboxylic acid. 182,183   
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4.3. Removal 
4.3.1. Protecting groups removed by acid. 
- tert-Butyl (tBu).176 It is used in both solution- and solid-phase synthesis. It is removed 
with high concentrations of TFA (solid phase and solution) or HCl in organic solvents 
(solution). In the latter case, it is effectively used along with Bpoc Nα- protection and Trt 
side chain protection or with Z group as Nα- protection.  It is stable to base-catalyzed 
hydrolysis and its bulkiness generally prevents DKP formation.184  
- Benzyl (Bn): See “other protecting groups” 
- 2-Chlorotrityl (2-Cl-Trt).185 It is removed with 1% TFA in DCM and is used as a 
semi-permanent protecting group for the synthesis of large peptides using a convergent 
approach.  
- 2,4-Dimethoxybenzyl (Dmb).186 It is removed with 1% TFA in DCM (6 x 5 min). Due 
to its high acid lability, it can be removed in the presence of  tBu-type protecting groups 
and also on Wang and PAL/Rink resins. It is used for Fmoc/tBu  SPS of  “head to tail” 
cyclic peptides.  
- 2-Phenylisopropyl (2-PhiPr).187 It is removed with 4% TFA in DCM for 15 min (Boc 
group is stable to these conditions).  
- 5-Phenyl-3,4-ethylenedioxythenyl derivatives (Phenyl-EDOTn).188 They have been 
recently developed and are removed using very small concentrations of TFA (0.01-
0.5%), being the most acid labile derivative the 5-(3,4-dimethoxyphenyl)-3,4-
ethylenedioxythenyl. 
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Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
tert-Butyl (tBu) 
 
 
90% TFA-DCM (solid 
phase and solution) or  
4 M HCl in dioxane 
(solution)  
Fmoc, Z,a Trt 
Alloc, pNZ,  
 
176,184 
2-Chlorotrityl (2-Cl-Trt) 
Cl
 
1% TFA-DCM 
 
Fmoc, Alloc 185 
2,4-Dimethoxybenzyl (Dmb) 
OMe
MeO
 
1% TFA-DCM  Fmoc, Alloc 186 
2-Phenylisopropyl (2-PhiPr) 
 
4% TFA-DCM Fmoc, Alloc 187 
5-Phenyl-3,4-ethylenedioxythenyl  
(Phenyl-EDOTn) 
 
0.01%-0.5% TFA-DCM 
and scavengers 
Fmoc  
a Catalytical hydrogenation removal. 
 
4.3.2. Protecting groups removed by base. 
-  9-Fluorenylmethyl (Fm).189,190 It is removed with secondary amines such as piperidine 
and DEA in DCM or DMF, and also by catalytical hydrogenation in solution.190 Used 
for SPS in the reverse N-C  direction,171  as well as for the preparation of “head to tail” 
cyclic peptides.191 
- 4-(N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino)benzyl  
(Dmab).192 It is removed by 2% of hydrazine·H2O-DMF (1:1) within minutes. It is 
stable to piperidine. 
- Methyl (Me) and Ethyl (Et).193 Methyl esters are removed by saponification (usually 
with LiOH), which can lead to epimerization and degradtion of Ser, Cys and Thr. 
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Nevertheless, they have been used extensively in classical peptide synthesis in solution. 
They are also a reasonable choice to obtain peptide amides by reaction of the methyl 
ester with ammonia. Ethyl esters have a similar behaviour to methyl esters but are more 
base-stable and therefore more prone to base- catalyzed side reactions.184 
- Carbamoylmethyl (Cam).194,195 It is used for solution synthesis. It is removed by 
saponification with NaOH or Na2CO3 in DMF. It is removed selectively in the presence 
of Boc and Z. Nevertheless, it can not be selectively removed in the presence of side 
chain Bn-protected Asp.    
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
9-Fluorenylmethyl (Fm) 
 
 15%  DEA or 20% 
piperidine-DMF or 
DCM  
 
Boc, Trt, Alloc 171,
189,
190,
191 
4-(N-[1-(4,4-dimethyl-2,6-
dioxocyclohexylidene)-3-methylbutyl]-
amino)benzyl  (Dmab) 
OO
H
N
 
2% hydrazine-H2O-
DMF (1:1) 
 
Boc, Fmoc, Trt,  192 
Methyl (Me) and Ethyl (Et) LiOH, NaOH or KOH  Boc, Z  184,
193 
Carbamoylmethyl (Cam) 
O
H2N  
NaOH or Na2CO3-
DMF-H2O 
Boc, Fmoc a Zb 195,
194 
a Diethylamine removal. 
b Only catalytical hydrogenation removal. 
 
4.3.3. Other protecting groups 
- Allyl (Al).163 It is removed using Pd(PPh3)4 (0.1 eq.) and PhSiH3 (10 eq.) as scavenger 
in DCM within minutes or  Pd(PPh3)4 and morpholine as nucleophile in THF-DMSO-
0.5 M HCl (2:2:1), both on solid phase and in solution.196 If removed on solid phase, 
washings with sodium N,N-diethyldithiocarbamate (0.02 M in DMF, 3 x 15 min) are 
carried out in order to remove Pd. Allyl C-terminal protection has been used for the 
synthesis of C-terminal modified peptides using the backbone linker (BAL) strategy,38 
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and recently for the synthesis of peptide analogs where α-carboxyl protection is 
necessary both in solution and on solid phase, such as the synthesis of cyclic peptides 
via head-to-tail cyclization, among others.197198,199,200,201 In these cases, when the Al 
group from the carboxyl group and the Fmoc from the amino group need to be removed, 
it is preferable to first remove the Al and then the Fmoc.  Removal of the Fmoc group 
first could increase the risk of allylation of the amino function during the removal of the 
Al.200,202 
- Benzyl (Bn). It is used mostly in solution synthesis. It is usually removed by catalytic 
hydrogenolysis. It can also be removed by saponification or hydrazinolysis to give the 
corresponding C-terminal. Acidolytic removal is also possible but harsh conditions are 
required. It is used in combination with the following Nα-protecting groups: Boc, Ddz, 
Bpoc and Troc.184  
- Phenacyl (Pac).203 It is used for synthesis in solution and removed by nucleophiles 
such as sodium thiophenoxyde or by treatment with Zn in AcOH.203,204 It is degraded 
and only partially removed by catalytical hydrogenation. It is more electrophilic than 
the methyl ester, thereby making Pac-protected amino acids prone to racemization 
during coupling because of a reversible cyclization mechanism (Figure 7).  
O
O
O
R1
H
H2N
O
OO
NH2
R1
H N
OO
R1
H
N
OO
R1 N
OO
R1
O
OO
NH2R
1
 
Figure 7. Racemization mechanism of Pac-protected amino acids. Adapted from  205 
 
- p-Nitrobenzyl (pNB). It is highly resistant to acids and removed using a variety of 
reducing agents such as Na2S, Na2S2O4, SnCl2 or catalytical hydrogenation.206,207,208,209 
Solid phase removal is performed by treatment with 8M SnCl2 in DMF containing 1.6 
mM AcOH and 0.2% phenol for 5 h at 25°C or three treatments of 30 min at 60°C.210 
Washings with DMF, MeOH, DMF and treatment with 8M benzene sulfinic acid in 
DMF for 30 min at 25°C and further washings with DMF and MeOH are performed to 
eliminate the quinonimine methide formed during the removal. 211 Use of a less 
concentrated and more easy to handle 6 M SnCl2 in DMF solution, substitution of 
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AcOH by HCl in dioxane and alternative  washings (DMF, DMF/H2O, THF/H2O, DMF 
and DCM, 3×30 s each) have been described in the case of Glu side chain protection.165   
These conditions should be easily adapted to the removal of the C-terminal protecting 
group.  Removal with TBAF in solution has also been proposed as an alternative to the 
reductive removal.212  
- 2-Trimethylsilylethyl (TMSE).213  It is removed with a quaternary ammonium fluoride 
such as TBAF or tetraethylammonium fluoride (TEAF) in DMF. It is stable to 
hydrogenolysis but unstable to anhydrous TFA. Nevertheless, Boc group can be 
removed selectively in its presence when HCl solutions in organic solvents are used. 
- (2-Phenyl-2-trimethylsiylyl)ethyl (PTMSE).214,215 It is removed by treatment with 
TBAF·3 H2O  in DCM in almost neutral conditions within 3-5 min. It is stable to the 
hydrogenolytic cleavage of Z and Bn ester groups, base-induced removal of Fmoc 
groups, palladium(0)-catalyzed removal of Alloc and even acidolytic cleavage of Boc 
groups if carried out under special conditions (p-TsOH or 1.2 M HCl in 2,2,2-
trifluoroethanol (TFE).  PTMSE esters are also stable under the conditions for amide 
bond formation in peptide synthesis or peptide condensation reactions and therefore it is 
considered a valuable novel carboxy protecting group. However, no studies on how the 
use of PTMSE affects the formation of aspartimides have been performed to date. 
-  2-(Trimethylsilyl)isopropyl (Tmsi).216 It is used for peptide synthesis in solution. It is 
removed with TBAF (8 eq.) in THF in 1-1.5 h. It significantly reduces DKP formation 
in comparison with TMSE.  
- 2,2,2-Trichloroethyl (Tce).217  It is used mainly for solution synthesis. It is removed 
with Zn dust in AcOH in similar conditions as Troc and therefore can be removed in the 
presence of Z, Boc, Alloc and Fmoc. Tce is stable even at pH 1 and therefore Boc can 
be removed selectively in its presence. It is not completely stable to hydrogenolysis.  
- p-Hydroxyphenacyl (pHP).218 It is removed by photolysis (λ= 337 nm) and used as a 
new phototrigger. It is stable to Boc removal. 
4,5-Dimethoxy-2-nitrobenzyl (Dmnb).219 It is a photolabile protecting group analogous 
to the NVOC group. It has been used for the synthesis of misacylated transfer RNAs, 
and recently for the synthesis of caged peptides.220   
- 1,1-Dimethylallyl (Dma).221 It is removed by treatment with Pd(PPh3)4 (10 mol %) in 
THF at room temperature followed by dropwise addition of  NMM (3 eq.) under 
nitrogen. PhSiH3, potassium 2-ethyl hexanoate or p-toluene sulfonic acid sodium salt 
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can be used instead of NMM. It is orthogonal to the Fmoc group and can be removed in 
the presence of Bn- and tBu-type groups but it is not stable to their acidolitic removal. 
- Pentaamine cobalt (III).222 It was proposed as a C-terminal-protecting group for the 
synthesis of side chain to side chain bicyclic peptides. It is described as orthogonal to 
Fmoc and Boc and is removed in solution by mild reduction with DTT in the presence 
of DIPEA in H2O-AcCN to the exchange labile Co (II) form. It has not been widely 
used since then. 
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Allyl (Al) 
 
Pd(Ph3)4 (0.1 eq.) and  
scavengers (usually 
PhSiH3, 10 eq.)-DCM 
Boc, Fmoc, 
pNZ,a Trt 
38,163, 
196,197,
198,199,
200,201,
202 
Benzyl (Bn) 
 
1) HF 
2) TFMSA 
3) H2 cat. 
4) NaOH in aqueous 
organic solvents 
Boc, b  Fmoc, 
pNZ,a Trt, Alloc 
184 
Phenacyl (Pac) 
O
 
1) sodium 
thiophenoxyde 
2) Zn in AcOH 
 
Boc, Z,a Trt 203,204 
p-Nitrobenzyl (pNB) 
 
O2N
 
1) SnCl2  in DMF 
2) Na2S·9H2O-H2O,  
0-5ºC 
3 ) Na2S2O 4, Na2CO3-
H2O, 40ºC 
4) H2 cat. 
5) TBAF-THF, DMF 
or DMSO 
Boc,Fmoc,  Z,a 
Trt, Alloc 
165,206
207,208,
209,210,
212 
2-Trimethylsilylethyl (TMSE) 
Me3Si  
TBAF or TEAF-DMF Z c  213 
(2-Phenyl-2-trimethylsilyl)ethyl 
(PTMSE) 
TBAF·3 H2O-DCM Fmoc, Z,c Alloc 214,215 
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Me3Si
 
2-(Trimethylsilyl)isopropyl (Tmsi) 
Me3Si
 
TBAF (8 eq.)-THF, 1-
1.5 h 
Zc 216 
 
 
2,2,2-Trichloroethyl (Tce) 
Cl3C  
Zn dust-AcOH Boc, Fmoc, Trt 217 
p-Hydroxyphenacyl (pHP) 
O
HO  
Photolysis     
(λ=337 nm) 
 
Boc, Trt 
 
218 
4,5-Dimethoxy-2-nitrobenzyl 
(Dmnb) 
MeO
MeO
NO2
 
Photolysis  
(λ>320 nm) 
 
Boc, Fmoc, Trt 219,220 
1,1-Dimethylallyl (Dma) 
 
Pd(PPh3)4 and 
scavengers: NMM, 
PhSiH3, potassium 2-
ethyl hexanoate or p-
Tos-OK-THF 
Fmoc 221 
Pentaamine cobalt (III) 
Co(NH)5·Cl2  
DTT, DIPEA-H2O-
AcCN 
Boc, Fmoc, Trt 222 
a Except catalytical hydrogenation removal. 
b Except repetitive removals. 
c Catalytical hydrogenation removal. 
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5. ASPARTIC (Asp) AND GLUTAMIC (Glu) ACIDS 
5.1. General  
The side chain carboxylic groups of Asp and Glu (Figure 8) must be protected in order 
to prevent their activation during peptide synthesis, which would lead to undesired 
branched peptides.   
Asp Glu
H2N COOH
COOH
H2N COOH
COOH
 
Figure 8. Aspartic (Asp) and  Glutamic (Glu) acids. 
 
Furthermore, in the case of Asp acid, the protecting groups used must also prevent or at 
least minimize the formation of aspartimide. Hydrolysis of the aspartimide during 
peptide synthesis renders two products: the α-peptide, which is the desired product, and 
the β-peptide, which is usally the major compound. Aminolysis of aspartimide by 
piperidine gives the corresponding α- and β-piperidides (Figure 9). 
 The same kind of intramolecular cyclization can also take place in the case of Glu, 
thereby leading to pyroglutamic formation.223  However, in the case of Glu the reaction 
is much less severe than with Asp. 
H
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NHydrolysis
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O
HO
H
N
OH
O
HN
O
O
Peptide (desired product)
Peptide
 (undesired product)
 
Figure 9. Aspartimide formation followed by piperidide formation upon piperidine 
treatment or hydrolysis rendering the α- and β-peptides. 
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Currently the most used protecting groups are tBu for the Fmoc/tBu strategy, and in the 
Boc/Bn strategy the cyclohexyl (cHx) group, which is replacing the classical Bn group 
because it is more effective at preventing the formation of aspartimide. 
5.2. Introduction of the protecting groups  
The protection of the side chain carboxylic acid can be achieved using several methods.  
The simplest one is the acid-catalyzed esterification of the free amino acid, where 
protonation of the amino group makes the α-carboxylic acid less reactive, thereby 
allowing the selective protection of the side chain.224,225  
Copper (II) and boron chelates used for the selective protection of the side chains of Lys 
and Orn are also applied for the selective protection of the side chain of Asp and Glu. 
After chelation and reaction with the appropiate protecting group halide, the chelate is 
removed in the usual way.180,181,141 Another alternative is the formation of an 
intramolecular anhydride between the two carboxylic acids, which leads to selective α-
protection thanks to the major electrophilicity of the α-carboxylic acid. This allows the 
protection of the side chain with a distinct protecting group, followed by the removal of 
the α-carboxylic acid protection.174,175  
5.3. Removal 
5.3.1. Protecting groups removed by acid 
- Benzyl (Bn). It is the classical protecting group in Boc/Bn chemistry and is removed 
with HF or TFMSA. However, it is more prone to acid-catalyzed aspartimide formation 
than the cyclohexyl group. Other possible removal conditions are listed in the table.  
- Cyclohexyl (cHx). It is removed with HF or TFMSA.226 227 It is widely used in the 
Boc/Bn solid- phase strategy. It is superior to the benzyl group at preventing acid-
catalyzed aspartimide formation because of its major steric hindrance.228  In addition, it 
is more resistant to acids than benzyl, thus making it more suitable for the synthesis of 
long peptides using the Boc/Bn strategy. 
- tert-Butyl (tBu). It is removed with 90% TFA in DCM (solid phase and solution) or 4 
M HCl in dioxane(solution). It is the most used protecting group in Fmoc/tBu chemistry, 
which is highly prone to aspartimide formation because of the reiterative use of 
piperidine.  The tBu group simply minimizes aspartimide formation because of its steric 
hindrance compared to other less hindered protecting groups such as allyl. However, 
although the tBu group is considered hindered in organic chemistry, it does not prevent 
aspartimide formation in those sequences prone to it.229 See also α-amino protection. 
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- β-Menthyl (Men).230 It is removed with HF or TFMSA and is resistant to TFA. It leads 
to less base-catalyzed aspartimides than the cyclohexyl group, but is not widely used. 
Sometimes diphenyl sulfide should be added as a scavenger to facilitate Men removal. 
231 
- β-3-Methylpent-3-yl (Mpe).232 It is removed with 95% TFA and is more sterically 
hindered than the tBu group and therefore less prone to aspartimide formation.  
- 2-Phenylisopropyl (2-PhiPr). It is removed with 1-2% TFA.233,187 It is used in the 
Fmoc/tBu strategy mostly for the protection of Glu but also of Asp. 234  It can be 
removed in the presence of tBu-type protecting groups and therefore it is useful for the 
preparation of cyclic peptides.235     
- 4-(3,6,9-trioxadecyl)oxybenzyl (TEGBz or TEGBn).236 It is a recently developed 
protecting group which is removed with TFA-DCM. It has been  used for the solid 
phase synthesis of “difficult” peptide sequences (those very prone to aggregate) because 
it minimizes chain aggregation during the synthesis. 
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Benzyl (Bn) 
 
1) HF 
2) TFMSA 
3) H2 cat. 
4) NaOH in aqueous 
organic solvents 
Boc, Fmoc, 
pNZ,a Trt, 
Alloc,  
 
 
Cyclohexyl (cHx) 
 
1) HF 
2) TFMSA 
Boc, Fmoc, 
pNZ, Trt, Alloc 
 
227,
228 
tert-Butyl (tBu) 
 
90% TFA-DCM (solid 
phase and solution) or 
4  M HCl(dioxane) 
(solution) 
Fmoc, Z,b Trt, 
Alloc,  pNZ  
 
229 
β-Menthyl (Men) 
 
HF, TFMSA-TFA Boc, Fmoc, Trt, 
Alloc, pNZ 
 
230,
231 
β -3-Methylpent-3-yl (Mpe) 
 
95% TFA-H2O Fmoc, Z, b Trt, 
Alloc 
232 
2-Phenylisopropyl (2-PhiPr) 1-2 % TFA-DCM Fmoc, Alloc 187,
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233,
234,
235 
4-(3,6,9-trioxadecyl)oxybenzyl (TEGBz 
or TEGBn) 
 
TFA-DCM Fmoc, Trt  
a Except catalytic hydrogenation removal. 
b Only catalytic hydrogenation removal. 
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5.3.2. Protecting groups removed by base 
- 9-Fluorenylmethyl (Fm).141,237,238 It is removed with secondary amines such as 
diethylamine or piperidine in DMF. It is stable to HBr in AcOH and TFA/thioanisole 
and non-stable to catalytic hydrogenation and not completely stable to HF even at 0ºC. 
It is used for the Boc/Bn strategy when orthogonal protection of the side chains is 
required.  
- 4-(N-[1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino)benzyl 
(Dmab).192,239 It is removed with 2% hydrazine within minutes in DMF-H2O. It is stable 
to 20% piperidine in DMF and TFA. Nevertheless, in some cases it can lead to 
pyroglutamyl-terminated peptides.240  
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
9-Flurorenylmethyl (Fm) 
 
Secondary amines: 
15%  DEA or 20% 
piperidine-DMF or 
DCM  
 
Boc, Trt, Alloc 141,
237,
238 
4-(N-[1-(4,4-dimethyl-2,6-
dioxocyclohexylidene)-3-methylbutyl]-
amino)benzyl  (Dmab) 
OO
H
N
 
2% hydrazine-DMF-
H2O 
Boc, Fmoc,  
Trt, Alloc 
192,
239,
240 
 
5.3.3. Other protecting groups 
- Benzyl (Bn). See protecting groups removed by acid. 
- Allyl (Al).163,164,241 It is removed with palladium and stable to TFA and bases. See also 
α-carboxylic acid protection.  
- p-Nitrobenzyl (pNB).242 It promotes aspartimide formation when used to protect Asp. 
See also α-carboxylic acid protection. 
- 2-(Trimethylsilyl)ethyl (TMSE).213,243 It is removed with fluorides, and is unstable to 
acids and bases, and stable to hydrogenolysis. It is used for the protection of Asp acid 
for cyclization on a Rink amide resin.244  
- (2-Phenyl-2-trimethylsiylyl)ethyl (PTMSE). See α-carboxylic acid protection. 
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- 4,5-Dimethoxy-2-nitrobenzyl (Dmnb). See α-carboxylic acid protection. 
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Allyl (Al) 
 
Pd(Ph3)4 (0.1 eq.) and  
scavengers (usually 
PhSiH3, 10 eq.) in 
DCM 
Boc, Fmoc, 
pNZ, a Trt 
163,
164,
241 
p-Nitrobenzyl (pNB) 
O2N
 
1) SnCl2  in DMF 
2) Na2S·9H2O in H2O, 
0-5ºC 
3 ) Na2S2O 4, Na2CO3 
in H2O, 40ºC 
4) H2 cat. 
5) TBAF-THF, DMF 
or DMSO 
Boc,Fmoc,  Z,a 
Trt, Alloc 
242 
Trimethylsilylethyl (TMSE) 
Me3Si  
TBAF or TEAF-DMF Z b 213,
243,
244 
(2-Phenyl-2-trimethylsilyl)ethyl 
(PTMSE) 
Me3Si
 
TBAF·3 H2O-DCM Fmoc, Z, b  
Alloc  
 
4,5-Dimethoxy-2-nitrobenzyloxycarbonyl 
(Dmnb) 
MeO
MeO
NO2
 
Photolysis (λ>320 nm) 
 
Boc, Trt  
a Except catalytical hydrogenation removal. 
b Catalytical hydrogenation removal. 
 
  
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
 46
6. AMIDE BACKBONE 
6.1. General 
The NH backbone is usually unprotected in peptide synthesis. However, at least three 
undesired interactions involving the  NH backbone have been described.  
First of all, peptide chains can aggregate during the synthesis as a result of intra- and 
inter-molecular interactions, thereby significantly reducing coupling and deprotection 
yields.245,246,247 Backbone protection (Figure 10) minimizes these aggregation 
phenomena by preventing the formation of hydrogen bonds and also because of steric 
hindrance. Thus, SPS of long peptidic sequences prone to aggregation is improved by 
protecting some amides of the peptide.248,249,250,251 
Secondly, nucleophilic attack of the amide NH of the amino acid before an Asp residue 
(usually Gly, Ser or Thr)69,227,62,252,253,254,255 to the β-carboxyl group of Asp renders 
aspartimide and the subsequent formation of β-peptide and other side products. (See 
Asp and Glu side chain protection). Aspartimide formation is more severe in the 
Fmoc/tBu strategy and with the Asp-Gly sequence but it can occur in many other cases. 
Finally, although less frequent, internal DKP formation involving the NH and the 
activated carboxylic acid of the previous amino acid has recently been described during 
fragment coupling (Figure 11)121  
The most used backbone protectors for the Fmoc/tBu strategy are pseudoprolines 
(Figure 12),256,257,251 2-hydroxy-4-methoxybenzyl (Hmb),258 and 2,4-dimethoxybenzyl 
(Dmb), and more recently 3,4-ethylenedioxy-2-thenyl (EDOTn) and 1-methyl-3-
indolylmethyl (MIM) 259  The pseudoproline concept is valid only for -hydroxy or thio 
amino acids such as Ser/Thr or Cys.  Although, the rest of protecting groups can be used 
for all amino acids, practically they are only used for Gly because of the difficulty of 
elongation of the peptide chain because of steric hindrance  260 
 
 
Figure 10. Partially backbone-protected peptide. BPG= backbone-protecting group Comentario [m4]: No estoy segura del 
cambio creo que quiere unificar la forma de 
poner los grupos protectores GP o Prot 
como en la figura 1 
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Figure 11. Internal DKP formation.  Adapted from ref. 121 
 
H
N
O
COOH
R  
Figure 12. Pseudoproline of Ser (R= H) and Thr (R= CH3). 
 
 6.2. Introduction of the protecting groups 
Due to the steric hindrance of the protected amino acid, it is incorporated usually 
through the corresponding dipeptides.  Thus, pseudoproline dipeptides are prepared by 
reaction of Fmoc-AA-Ser or Fmoc-AA-Thr with 2,2-dimethoxypropane.261  Most of the 
other backbone protectors are introduced by reductive amination of the aldehyde of the 
protecting group with the amine of the corresponding amino acid, followed by either α-
amino protection or dipeptide formation.262,258,259 
6.3. Removal 
 6.3.1. Protecting groups removed by acid 
- Pseudoprolines (ΨPro). The most used are dimethyloxazolidines (Ψ Me,Mepro) because 
of their major acid lability (removed by TFA within minutes)261 Pseudoproline 
derivatives have been extensively applied to the synthesis of difficult peptides.257,,263  
However, they are limited to Ser and Thr.  Dimethylthiazolidines (Cys pseudoprolines) 
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have also been described but they are not so widely used because of their major acid 
stability (removed with TFA within hours). 
- 2-Hydroxy-4-methoxybenzyl (Hmb).258 It is used mainly as Fmoc-(FmocHmb)AA1-
OH 264 or as Fmoc-AA2-(Hmb)AA1-OH but also as Fmoc(Hmb)AA1-OH. 265 It is 
removed with TFA.  The main advantage of the Hmb group compared with other 
backbone protectors such as Dmb is that the coupling on Hmb-amino acids is easier.  
Thus, Hmb is not restricted to Gly, and derivatives of more hindered amino acids can be 
used. However, the presence of a free hydroxyl group can be a problem in depsipeptide 
synthesis or in post-synthetic phosphorylations. 
- 2,4-Dimethoxybenzyl (Dmb).266. It is removed with high concentrations of TFA. Its 
major inconvenience is its bulkiness, which limits its use for non-sterically hindered 
amino acids (mainly Gly),255 or for direct coupling of Dmb-protected dipeptides (Fmoc-
AA’-(Dmb)AA-OH). 267  
- 2,4,6-Trimethoxybenzyl (Tmob).268 It is removed with TFA and has been used for the 
Fmoc/tBu SPS of highly hydrophobic peptides.269  Although it is not as widely used as 
Dmb, coupling on 2,4,6-trimethoxybenzyl amines of amino acids is described to be 
faster than in the case of the less hindered 2,4-dimethoxybenzyl amines.258 
- 1-Methyl-3-indolylmethyl (MIM) and 3,4-Ethylenedioxy-2-thenyl (EDOTn).259 These 
are recently developed backbone protectors for the Fmoc/tBu strategy. They are 
completely removed with TFA-DCM-H2O (95-2.5-2.5) in 1 h. Both are more acid-labile 
than the 2,4-dimethoxybenzyl group, and EDOTn is less sterically hindered, thus 
couplings on EDOTn amino acids are faster.   
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Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Pseudoprolines (oxazolidines) 
Pseudoprolines 
H
N
O
COOH
R  
R= H (Ser) or Me (Thr) 
95%  TFA and 
scavengers 
 
 
 
 
 
 
 
Fmoc, Alloc 257,
261,
263 
2-Hydroxy-4-methoxybenzyl (Hmb) 
OMe
HO
 
95%  TFA and 
scavengers 
 
Fmoc, Alloc 258,
264,
265 
2,4-Dimethoxybenzyl (Dmb) 
OMe
MeO
 
95%  TFA and 
scavengers 
 
Fmoc, Alloc 255,
266,
267 
2,4,6-Trimethoxybenzyl (Tmob) 
OMe
MeO OMe
 
95%  TFA and 
scavengers 
 
Fmoc, Alloc 258,
268,
269 
1-Methyl-3-indolylmethyl (MIM) 
N
Me  
TFA-DCM-H2O 
(95:2.5:2.5) 
Fmoc, Alloc 259 
3,4-Ethylenedioxy-2-thenyl (EDOTn) 
S
OO
 
TFA-DCM-H2O 
(95:2.5:2.5) 
 
 
Fmoc, Alloc 259 
 
 
6.3.2. Other protecting groups 
- 4-Methoxy-2-nitrobenzyl.270 It is removed by photolysis at λ=360 nm for more than 2 h 
using Cys (200 mmol per 1 mmol of 4-methoxy-2-nitrobenzyl) as scavenger.  This is a 
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backbone protector, fully compatible with Boc chemistry, thereby allowing the 
obtention of backbone-protected peptides after HF cleavage.  
- (6-Hydroxy-3-oxido-1,3-benz[d]oxathiol-5-yl)methyl 271,272 and  2-hydroxy-4-methoxy-
5-(methylsulfinyl)benzyl.273 These are safety-catch backbone protectors which become 
unstable to TFA after reduction of the sulfoxide to sulfide. (6-Hydroxy-3-oxido-1,3-
benzoxathiol-5-yl)methyl is removed with 20 eq. each of  NH4I and (CH3)2S in TFA at 
0°C over 2 h, whereas 2-hydroxybenzyl-4-methoxy-5-(methylsulfinyl) is removed with 
SiCl4-TFA-anisole-ethanedithiol, (5:90:2.5:2.5), for 2 h at room temperature. Acylation 
as well as acyl migration is faster in the case of the latter. 
- Boc-N-methyl-N-[2-(methylamino)ethyl]carbamoyl-Hmb (Boc-Nmec-Hmb).274 It is a 
recently developed protecting group. It has been used for solid phase synthesis. After 
the removal of the Boc group with TFA during the cleavage of the peptide from the 
resin, the Nmec moiety is removed via an intramolecular cyclization in basic conditions 
(N-methylmorpholine (10 eq) in DMF/H2O (3:7), 4 -8 h), leading to the Hmb protected 
peptide. Then, Hmb is removed with 95% TFA and scavengers. The main advantage of 
the Boc-Nmec-Hmb group is that after Boc removal, a cationic peptide is obtained 
which increase the solubility of insoluble peptides making their purification easier. 
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
4-Methoxy-2-nitrobenzyl  
OMe
O2N
 
Photolysis (λ=360 nm) 
and Cys as scavenger 
Boc, Z, a Trt, 
Alloc  
270 
(6-Hydroxy-3-oxido-1,3-
benz[d]oxathiol-5-yl)methyl 
HO
O
S O
 
NH4I (20 eq.) and 
(CH3)2S (20 eq.)-TFA, 
2 h, 0°C. 
Boc, Fmoc,Trt 271,
272  
2-Hydroxy-4-methoxy-5-
(methylsulfinyl) benzyl 
SiCl4-TFA-anisole-
ethanedithiol, 
(5:90:2.5:2.5), 2 h, rt 
Boc, Fmoc,Trt 273 
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O
HO
S
Me
O
Me  
Boc-N-methyl-N-[2-
(methylamino)ethyl]carbamoyl-Hmb 
(Boc-Nmec-Hmb) 
 
i) 25-50% TFA-DCM 
ii) N-methylmorpholine 
(10 eq) in DMF/H2O 
(3:7), 4 -8 h 
iii) 95%  TFA and 
scavengers 
 
Fmoc, Trt  
a Except catalytical hydrogenation removal.
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7. ASPARAGINE (Asn) AND GLUTAMINE (Gln)  
7.1. General  
Asn and Gln (Figure 13) are often used without side chain protection.  
Asn Gln
H2N COOH
CONH2
H2N COOH
CONH2
 
Figure 13. Asparagine (Asn) and  Glutamine (Gln) 
 
Nevertheless, unprotected derivatives show poor solubility and therefore slow coupling 
rates. In addition, their free primary amides can undergo two main side reactions.  
1)  Dehydratation during the coupling (Figure 14), which is a base-catalyzed side 
reaction and therefore more favoured in those coupling protocols that involve the use of 
base. It can be minimized using the corresponding Nα-protected pentafluorophenyl 
esters or carbodiimide-mediated couplings in the presence of HOBt.275,276 Dehydratation 
is more important in  the Fmoc/tBu strategy than in the Boc/Bn one because in the latter, 
the use of  HF apparently reverts the reaction, whereas in  the former TFA is not acidic 
enough to revert to the amide.276  
H
N
O
ActPG
N
O
HH
O
O
N
H
NPG
H
H
N
O
OHPG
C N
B B  
Figure 14. Dehydratation of Asn.  Adapted from 277. 
 
2) Pyroglutamyl (Figure 15) formation is a weak acid-catalyzed side reaction that occurs 
on N-terminal Gln that leads to truncated peptidic chains. Being an acid-catalyzed 
reaction, it has more importance in the Boc/Bn strategy and can be minimized by 
reducing exposure to weak acids.278  
H2N
O
H2N
O
N
H
H+
H
N
O
N
HO
Pyroglutamyl  
Figure 15. Pyroglutamyl formation.  
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Adequate protection of Asn and Gln side chains prevents both side reactions. As for 
dehydratation, it is not necessary for the protecting group of choice to be stable during 
the whole peptide synthesis, but only during the coupling step.  Furthermore, protection 
of Asn and Gln side chains also increases coupling yields by confering more solubility 
to the corresponding Asn and Gln derivatives and probably reducing the formation of 
hydrogen bonds that stabilize secondary structures. 
Removal of the protecting groups is usually easier in Gln than in Asn, being particularly 
difficult in N-terminal Asn because of the proximity of the free and therefore protonated 
α-amino group.281,279,280 
Currently, the most used protecting groups are Xan (9-xanthenyl) and Trt, which are 
compatible with both Boc/Bn and Fmoc/tBu strategies. In the case of the former, the 
Xan group protects Asn and Gln side chains only during the coupling and is removed 
during TFA treatments for Boc removal.  
7.2. Introduction of the protecting groups 
Protection is usually performed via acid-catalyzed reaction of the corresponding alcohol 
with Z-Gln or Z-Asn, followed by catalytic hydrogenolysis to eliminate the Z group and 
Fmoc or Boc Nα protection. 281,282 In the case of 9-xanthenyl, the direct protection of the 
Fmoc-Asn and Fmoc-Gln has also been described. 283 
7.3. Removal  
7.3.1. Protecting groups removed by acid- 9-Xanthenyl (Xan).282 It is removed by 
90% TFA and scavengers. In contrast to Trt, no extra reaction time is required when the 
α-amino of Asn is free.279 Xan is used in both the Boc/Bn and Fmoc/tBu strategies.282,283 
In the case of the Boc strategy, Xan is eliminated during TFA treatments to remove the 
Boc group; however, Asn or Gln residues can undergo dehydratation only during the 
coupling and thus, Xan elimination after it is a minor problem.283  
- Trityl  (Trt).280,281 It is removed with TFA-H2O-EDT (90:5:5), and used in both the 
Boc/Bn and Fmoc/tBu strategies. The time required for removal increases from 10 min 
to more than 4 h when the α-amino of Asn is free. Scavengers must be used to prevent 
Trp alkylation. It is stable to bases and catalytic hydrogenolysis. 
- 4-Methyltrityl (Mtt).284,280 It is a more acid-labile alternative to the Trt group (95% 
TFA, 20 min), and is particularly useful when the α-amino of Asn is free.  
- Dimethylcyclopropylmethyl (Dmcp) or Cyclopropyldimethylcarbinyl (Cpd).285,286 It is 
removed with TFA-thioanisole-EDT-anisole (90:5:3:2), being another more acid labile 
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alternative to Trt, especially when the α-amino of Asn is free. It is more soluble and 
coupling rates are better than with the Trt group. 
- 4,4’-Dimethoxybenzhydryl (Mbh).287,288 It is used mainly in the Boc/Bn strategy but 
also in the Fmoc/tBu one. Its removal using TFA is slow and requires scavengers to 
prevent alkylation of Trp.275  
- 2,4,6-Trimethoxybenzyl (Tmob).289 It is removed with 95% TFA and scavengers. It is 
more acid-labile, more soluble and gives less side reactions during coupling than Mbh-
protected derivatives.  However, it is not currently widely used because it can cause 
alkylation of Trp and is reported to give worse results than the Trt group.290,281  
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Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
9-Xanthenyl (Xan) 
O  
90% TFA-scavengers Fmoc, Trt, 
Alloc 
279,
282,
283 
Trityl  (Trt) 
 
TFA-H2O-EDT 
(90:5:5) 
Fmoc, Trt, 
Alloc 
280,
281 
4-Methyltrityl (Mtt) 
 
95% TFA Fmoc, Trt, 
Alloc 
280,
284 
Dimethylcyclopropylmethyl (Dmcp)  or 
Cyclopropyldimethylcarbinyl (Cpd)  
 
TFA-thioanisole-EDT-
anisole (90:5:3:2) 
Fmoc, Alloc 285,
286 
4,4’-Dimethoxybenzhydryl (Mbh) 
OO  
1M TMSBr-
thioanisole-EDT-m-
cresol in TFA  (2 h at 
0ºC)   
Fmoc, Alloc 275,
287,
288 
2,4,6-Trimethoxybenzyl (Tmob) 
OO
O  
95% TFA-DCM and 
scavengers 
 
 
Fmoc, Alloc 281,
289,
290 
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8. ARGININE (Arg)  
8.1. General  
Protection of the guanidino group of Arg (Figure 16) is required to prevent 
deguanidination, which renders Orn (Figure 17) 291 and δ-lactam formation (Figure 18) 
277 as a result of the nucleophilicity of the guanidino group. Arg side chain protection 
remains unsolved in peptide synthesis because of the difficulty to remove the protecting 
groups. 
H2N COOH
HN
HN NH2
'

 
Figure 16. Arginine (Arg) 
 
Since the guanidino group is basic (pKa= 12.5), it remains protonated in most of the 
conditions used for peptide synthesis.292,293 To prevent deprotonation in Fmoc/tBu SPS, 
washings with 0.25 M HOBt are carried out between Fmoc removal and the next 
coupling.294 However, if deprotonation takes place, deguanidination occurs after 
acylation of the neutral guanidino group. This drawback stimulated research into 
protecting groups for Arg.  
H2N
O
peptide
PG-N
HN NH-PG
H
N C
R
O
OX
PG
Base
H
N
O
peptide
PG-HN
N NH-PG
H
N C
R
O
PG
O
H
N
R
PG
H
N
O
peptide
PG-HN
H
N C
R
O
PG
N
N
O
R
PG-HN
Deguanidilated peptide
PG
Figure 17. Acylation of the side chain of Arg during amino acid coupling, followed by 
base-catalyzed deguanidination. Adapted from 291 
 
Arg derivatives tend to be worse acylating reagents compared with other amino acid 
derivatives, mainly because of the formation of the -lactam from the activated species 
(Figure 18).   In a solid-phase mode, the presence of the -lactam does not translate in 
an impurity in the crude reaction, because it is not reactive but it is translated in a less 
active species to be coupled.  
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H
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NPG
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-lactam
 
Figure 18. Mechanism of δ-lactam formation. R= H or protecting group. Adapted from 
277. 
 
In principle, protection of all the nitrogens of the guanidino group is required to fully 
mask its nucleophilicity. However, diprotection and monoprotection are easier to 
achieve and minimize side reactions when bulky and electron-withdrawing protecting 
groups are used.  
The most used protecting strategy is sulfonyl protection of the -amino function.  For 
the Boc/Bn strategy, the most used group is Tos while for the Fmoc/tBu strategy the 
most popular protecting groups are Pbf (pentamethyl-2,3-dihydrobenzofuran-5-
sulfonyl) and Pmc (2,2,5,7,8-pentamethylchroman-6-sulfonyl). However, both, but 
particularly Pmc, are too acid stable and their removal in peptides with multiple Args is 
especially problematic. 
8.2. Introduction of the protecting groups 
It depends on the nature of the protecting group, in the case of sulfonyl-protecting 
groups, which are the most used ones, they are usually introduced by reaction of the 
corresponding sulfonyl chloride with Z-Arg-OH in H2O-acetone using NaOH as a base. 
To obtain the corresponding Fmoc/Boc derivative, the Z group is removed by catalytic 
hydrogenolysis and the Fmoc/Boc group is incorporated under regular conditions.295  
8.3. Removal  
8.3.1. Protecting groups removed by acid. 
Arylsulfonyl ω-protection: Although this kind of protection does not fully prevent δ-
lactam formation, this process can be minimized by using carbodiimides in the presence 
of HOBt derivatives to decrease the activity of the active O-acylisourea.184 
 - Tosyl (Tos). It is removed with HF, TFMSA-TFA-thioanisole or Na/NH3.296 It is the 
most used protecting group in the Boc/Bn solid phase strategy.297  
- 2,2,5,7,8-Pentamethylchroman-6-sulfonyl (Pmc).295 It  is widely used in the Fmoc/tBu 
solid phase strategy. It is removed by TFA-scavengers. Currently, it is being replaced 
by the Pbf group. 
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- 2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl (Pbf).298 It is removed by 
TFA-scavengers and is more acid-labile than the Pmc group. Currently, it is the best 
Arg-protecting group for the Fmoc/tBu solid phase strategy, although it is still too acid- 
stable in peptides with multiple Arg-containing peptides where long reaction times are 
required. 
- Mesitylyl-2-sulfonyl (Mts).299,300 It is removed with TFMSA-TFA-thioanisole. It is 
used in the Boc/Bn solid phase strategy and is more acid-labile than the tosyl group. 
- 4-Methoxy-2,3,6-trimethylphenylsulfonyl (Mtr).301 It is removed by TFA-thioanisole. 
Although it is still used, it has been mostly replaced by the more acid-labile Pmc or Pbf 
in Fmoc/tBu chemistry. 
- 1,2-Dimethylindole-3-sulfonyl (MIS).302 It is a recently developed protecting group, 
which is much more TFA-labile than Pbf. It is completely removed with 50% TFA in 
30 min, even in multiple Arg-containing peptides. 
Other kinds of Arg protection 
- ω,ω’-bis-tert-Butyloxycarbonyl (bis-Boc).303 It is removed with 90-95% TFA in the 
presence of scavengers, prevents deguanidination but does not completely prevent δ-
lactam formation.304,305 The coupling rates of bis-Boc-protected Arg are low. 
- ω-5-Dibenzosuberenyl (Suben), 5-Dibenzosuberyl (Sub) and 2-Methoxy-5-
dibenzosuberyl (MeSub).306 They are the most acid-labile derivatives (removed with 25-
50% TFA) and are reported to minimize δ-lactam formation and deguanidination 
because of their steric hindrance. Although they look very promising, they have not 
been widely used. 
- ω-Nitro (NO2).307 It prevents δ-lactam formation and deguanidination in most cases. It 
can be removed with HF (SPS) or catalytic hydrogenolysis. In both cases long reaction 
times are required, which is an inconvenience in the case of sensitive peptides. For 
instance, in the case of hydrogenolysis, partial hydrogenation of Trp or even Phe can 
occur.308 Due to the clean removal of the nitro group by hydrogenolysis and its low cost, 
nitro protection is still used for large-scale solution synthesis of peptides 309,310 and even 
for SPS, where the nitro group is removed by hydrogenolysis after the cleavage from 
the resin.311 
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Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
 Protonation 
NH
NH2H2N  
    -     - 294 
p-Toluenesulfonyl (Tos) 
S
O
O
HN
N
H
NH
 
1) HF 
2) TFMSA-TFA-
thioanisole 
3) Na/NH3  
Boc, Fmoc, Trt, 
Alloc 
296,
297 
2,2,5,7,8-Pentamethylchroman-6-
sulfonyl (Pmc) 
O S
O
O
HN
N
H
NH
 
90% TFA-scavengers 
(H2O and TIS) several 
hours. 
 
Fmoc, Trt, 
Alloc 
295 
2,2,4,6,7-Pentamethyl-2,3-
dihydrobenzofuran-5-sulfonyl (Pbf) 
S
O
O
O
HN
N
H
NH
 
90 TFA-scavengers 
(H2O and TIS)  1 h 
(longer times in 
multiple arginine 
containing peptides) 
 
Fmoc, Trt, 
Alloc 
298 
Mesitylyl-2-sulfonyl (Mts) 
S
O
O
HN
N
H
NH
  
TFMSA-TFA-
thioanisole 
Boc, Fmoc, Trt, 
Alloc  
299,
300 
4-Methoxy-2,3,6-
trimethylphenylsulfonyl (Mtr) 
O S
O
O
HN
N
H
NH
 
95% TFA-thioanisole Fmoc, Trt, 
Alloc 
301 
1,2-Dimethylindole-3-sulfonyl (MIS) 
N
S
O
O
 
50% TFA and 
scavengers, 30 min 
Fmoc, Alloc 302 
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ω,ω’-bis-tert-Butyloxycarbonyl (bis-Boc) 
NH
N
H
N
OO
O O
 
90- 95% TFA and 
scavengers  
Fmoc, Alloc 303,
304,
305 
5-Dibenzosuberenyl (Suben) 
H
N
HN
HN
 
25-50% TFA Fmoc, Alloc  306 
5-Dibenzosuberyl (Sub) 
H
N
HN
HN
 
25-50% TFA Fmoc, Alloc  306 
2-Methoxy-5-dibenzosuberyl (MeSub) 
H
N
HN
HN
O
 
25-50% TFA Fmoc, Alloc 306 
Nitro (NO2) 
NH
N
H
HN NO2
 
HF (solid phase) 
H2  cat. (solution) 
Boc, Fmoc, 
Alloc 
307,
308,
309,
310,
311 
 
8.3.2. Protecting groups removed by base 
- Trifluoroacetyl (tfa). It has been applied recently for the protection of guanidines used 
in solution Boc peptide synthesis and Fmoc/tBu SPPS. However, although there are 
references of tfa-protected Arg derivatives,312,313,314 to date it has not been implemented 
for Arg protection in peptide synthesis.  
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Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Trifluoroacetyl (tfa) 
 
1) K2CO3-MeOH-H2O 
(solution)  
2) K2CO3-MeOH-DMF-
H2O (solid phase) 
Boc, Fmoc, Z, a 
Trt,  Alloc 
312, 
313, 
314 
a Catalytical hydrogenation  removal. 
 
8.3.3. Other protecting groups 
-  Nitro (NO2). See protecting groups removed by acid. 
- ω,ω’-Bis-benzyloxycarbonyl (bis-Z).315 Its removal by catalytic hydrogenation requires 
long reaction times. It is used mostly in Boc/Bn chemistry but also in the Fmoc/tBu 
strategy.  
- ω,ω’-bis- allyloxycarbonyl (Alloc).164 It is removed with Pd(PPh3)4 and scavangers 
(dimethylbarbituric acid)316  and is compatible with the Boc/Bn solid phase strategy.  
The base treatment required to remove the Fmoc group also eliminates one of the Alloc 
groups.  
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
ω,ω’-bis-benzyloxycarbonyl (Z) 
NH
N
H
N
OO
O O
 
H2 cat. (long time) Boc, Fmoc, Trt 315 
ω,ω’-bis- allyloxycarbonyl (Alloc) 
NH
N
H
N
OO
O O
 
Pd(PPh3)4, barbituric 
acid 
Boc, Fmoc, Z, a 
Trt 
164,
316 
a Except catalytical hydrogenation removal. 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
 62
9. CYSTEINE (Cys) 
9.1. General 
Protection of the side chain of Cys (Figure 19) is mandatory in peptide synthesis 
because the nucleophilic thiol can otherwise be acylated, alkylated or oxidized to 
disulfide by air.  
H2N COOH
SH
Cys  
Figure 19. Cysteine (Cys) 
 
Nevertheless, even protected Cys can undergo several side reactions. The most relevant 
are listed here. 
- Oxidation and alkylation of the thioether.  Although less critical than in the case of 
Met, it can also occur.317,318,319  Oxidation of the Cys residues during global 
deprotection can be minimized using 10% of H2O as scavenger.121  
- β-Elimination (Figure 20) occurs when protected Cys is exposed to strong bases, such 
as sodium in liquid ammonia (required to remove the Benzyl group), alkaline conditions 
or hydrazylnolysis, but also to strong acids such as HF. This side reaction is particularly 
critical in the case of C-terminal Cys, which in the Fmoc/tBu strategy undergoes β-
elimination followed by piperidine addition to give piperidylalanine residue. The extent 
of β-elimination also depends strongly on the protecting group used, StBu being the 
worst case followed by Acm and Trt.320,321 The Bn group can also produce β-
elimination. 
NH
O
N
H
S
PG
HH
N
H
N
O
N
H
H
N
H
N
O
N
H
N
Piperidyl alanine  
Figure 20. Base-catalyzed β-elimination of protected Cys followed by piperidine 
addition leading to piperidyl alanine. 
- Reaction with carbocations resulting from the elimination of protecting groups: after 
its deprotection, Cys can react with the cations generated in acidic conditions.  For 
instance, S-tert-butylated Cys has been observed after the removal of the Boc group or 
after global deprotection in a Fmoc/tBu strategy.322  
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- Reattachment to the resin: resin bound carbocations generated in the acidolytic 
cleavage from resins can react with both protected and unprotected Cys, thus causing 
reattachment of the peptide to the resin.323 
- Transfer of Acm (Acetamidomethyl) group to Ser, Thr, Gln and Tyr during Acm 
removal. 324 325 326 
- Formation of thiazolidines of N-terminal Cys (Figure 21) can take place if His- 
protecting groups such as Bom (benzyloxymethyl) or Bum (tert-butyloxymethyl), 
which generate formaldehyde when removed, are present. It can be minimized using 
Cys as scavenger. 327,328 
H2N
O
N
H
HS
H
O
H
O
N
H
H
N
S
Thiazolidine  
Figure 21. Thiazolidine formation by reaction of N-terminal Cys with formaldehyde. 
 
- Racemization: Cys is highly prone to racemize during the anchoring to the solid 
support or during the couplings.329 330 The extent of the racemization also depends on 
the S-protecting groups (StBu > Trt > Acm > MeBn > tBu)331,332,333,334,335 and coupling 
methods used (favoured if pre-activation in the presence of base is performed and in the 
coupling methods involving the use of base).  Epimerization of the Cys linked to a 
hydroxyl resin can even take place during the synthesis as a result of the repetitive base 
treatments to remove the Fmoc group, 2-chlorotrityl resin being the least prone to this 
process.331,336  
The most used protecting groups for the Fmoc/tBu strategy are the Acm or Trt groups, 
when the desired product is the disulfide, and the Trt group when the desired product is 
the free thiol.  For the Boc/Bn strategy, Bn, and Meb (p-methylbenzyl) are the most 
used to obtain the free thiol and Acm to obtain disulfides.  
9.2. Introduction of the protecting groups   
The Cys thiol shows high nucleophilicity, therefore Cys thiol protection is usually 
carried out using fully unprotected Cys as starting material. The S-protecting agents 
used can be alkyl halides or tosylates, under acidic or basic conditions, or alcohols, 
which are dehydrated under acidic conditions. Benzyl-type protection can also be 
performed via reduction of the thiazolidine formed with the corresponding 
benzaldehyde.337 
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9.3. Removal  
The classification of the protecting group of Cys is particularly complex because most 
of the protecting groups used can be removed either by oxidation to the disulfide bridge 
or by other mechanisms. The following classification has drawn up taking into account 
these other mechanisms but also indicating the conditions for the oxidative removal in 
each particular case. 
9.3.1. Protecting groups removed by acid. 
- p-Methylbenzyl (Meb).338  More acid-labile than the Bn, it is removed with HF and 
scavengers at low temperatures.339 340 It is gradually replacing the Bn in the Boc/Bn 
solid phase strategy. It can also be removed with Tl(III) trifluoroacetate or with 
MeSiCl3 in the presence of diphenylsulfoxide to yield disulfide bridges.  However, p-
methoxybenzyl (Mob) is usually a cleaner option.341  
- p-Methoxybenzyl (Mob).338 It is more acid-labile than Meb and is also used in the 
Boc/Bn solid phase strategy. However, it is partially removed in the repetitive 
treatments to remove the Boc group when long peptide sequences are synthesized.338 It 
is completely removed by HF at 0ºC and scavengers, TFMSA/TFA342 and Hg (II) 
acetate or trifluoroacetate in TFA or AcOH respectively.343  It can be selectively 
removed in the presence of Meb using Ag(I) trifluoromethanesulfonate in TFA.344 An 
intramolecular disulfide bridge between two Cys(Mob)-protected residues can be 
formed by removing the Mob group with MeSiCl3 or SiCl4 in TFA in the presence of 
diphenyl sulfoxide at 4ºC in 30 min.345 In addition, oxidative removal with Tl(III) 
trifluoroacetate also leads to the formation of a disulfide bridge by reaction with a free 
Cys side chain.  
- Trityl (Trt).346 It is removed with TFA and scavengers, such as triisopropylsilane (TIS) 
to prevent retritylation, or AgNO3.347  It is used for the Fmoc/tBu strategy although 
Fmoc-Cys(Trt) can undergo racemization in basic carboxyl activation conditions.332 It 
can also be removed by oxidation with iodine, thereby leading to a dilulfide bridge by 
reaction with a free Cys side chain. Other oxidative removals are listed in the table.348 
- Monomethoxytrityl (Mmt).349 It is removed with diluted TFA and scavengers. It is 
considerably more acid-labile than the S-trityl group and can be removed selectively in 
its  presence as well as in the presence of tBu-protecting groups. Oxidative removal is 
similar to the case of the Trt group. 
- Trimethoxybenzyl (Tmob).350 It is another more acid-labile alternative to the Trt group 
for the Fmoc/tBu strategy. It is removed with diluted TFA (5-30%) and scavengers; 
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however, the trimethoxybenzyl cation resulting from its cleavage can alkylate Trp 
residues.  
- 9-Xanthenyl (Xan).332 It has similar stability features to Mmt, thus, it can also be 
removed selectively in the presence of  S-trityl  and tBu-protecting groups or Rink and 
PAL handles. 
- 2,2,4,6,7-Pentamethyl-5-dihydrobenzofuranylmethyl (Pmbf).351 It is a relatively new 
highly acid-labile protecting group (Fmoc/tBu chemistry). It is removed with TFA-TES-
DCM (0.5-5-94.5) in 2 h to render the free thiol. Alternatively, treatment with I2 yields 
the disulfide bridge. This protecting group has been succesfully applied to obtain 
oxytocin.  
- Benzyl (Bn).352 It is removed with HF at 25ºC or Na in liquid ammonia. However, 
although still used, it is being replaced by other benzyl derivatives that do not require 
such harsh conditions for their removal.  
- tert-Butyl (tBu) and 1-Adamantyl (1-Ada).353 Both are fully stable to TFA and can 
therefore be used in the Boc/Bn strategy. They are also quite stable to HF at low 
temperatures but cleaved at higher temperatures in the presence of scavengers.335 They 
are also stable to Ag (I) trifluoromethanesulfonate in TFA,344 which quantitatively 
removes the S-Mmt group, and also to iodine oxidation. Other possible cleavage 
conditions are listed in the table.343  
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Name and Structure 
Removal conditions 
(final S form) 
Stability to 
the removal 
of 
Compatibility 
with the most 
important sulfur 
protecting groups 
 
Ref 
p-Methylbenzyl (Meb) 
 
1) HF, scavengers 
(SH) 
2) MeSiCl3 or SiCl4, 
TFA, Ph2SO, (S-S) 
3) Tl(TFA)3 (S-S) 
Boc, Fmoc, 
Trt, Alloc 
Trt,a Acm, StBu, 
Npys, Fmb 
338,
339,
340,
341 
p-Methoxybenzyl (Mob) 
  EMBED ChemDraw.Document.6.0  
O
 
1) HF, scavengers 
(SH) 
2) TFMSA-TFA (SH) 
3) Hg(OAc)2 in TFA 
or   Hg(TFA)2, in 
AcOH (SH) 
4) Ag (TFMSO) 
(SH) 
5) Tl(TFA)3 (S-S) 
6) MeSiCl3 or SiCl4 
TFA, Ph2SO, 4ºC,  30 
min, (S-S) 
Boc,c Fmoc, 
Trt, Alloc 
Trt,a Acm, StBu, 
Npys, Fmb 
338, 
342, 
343,
344,
345 
Trityl (Trt) 
 
1) 95% TFA, 
scavengers (SH) 
2) Hg(OAc)2 (SH)  
3) AgNO3  (SH) 
4) I2 (S-S) 
5) Tl(TFA)3 (S-S) 
Fmoc, Alloc Meb/Mob,a Acm,d 
StBu, Npys, Fmb 
332,
346,
347,
348 
Monomethoxytrityl (Mmt) 
O
 
1) 1% TFA, 
scavengers (SH) 
2) Hg(OAc)2 (SH) 
3) AgNO3 (SH) 
4) I2 (S-S) 
5) Tl(TFA)3 (S-S) 
Fmoc, Alloc Meb/Mob,a Acm,d 
StBu, Npys, Fmb 
349 
Trimethoxybenzyl (Tmob) 
O
O
O  
5-30% TFA, 
scavengers (SH) 
2) I2 (S-S) 
3) Tl(TFA)3 (S-S) 
 
Fmoc, Alloc  350 
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9-Xanthenyl (Xan) 
O  
1% TFA , scavengers 
(SH) 
Fmoc, Alloc  332 
2,2,4,6,7-pentamethyl-5-
dihydrobenzofuranylmethyl (Pmbf) 
 
1) TFA-TES-DCM 
(0.5-5-94.5) in 2 h 
(SH) 
2) I2 (S-S) 
 
Fmoc  351 
Benzyl (Bn) 
 
1) HF (SH) 
2) Na, NH3 (SH) 
Boc, Fmoc, 
Trt, Alloc 
 352 
tert-Butyl (tBu) 
 
1) HF (20ºC) 
scavengers (SH) 
2)TFMSA-TFA and 
scavengers (SH) 
3) Hg(OAc)2 in TFA 
(SH) 
Boc, Fmoc, 
Trt, Alloc 
 335,
343,
344,
353 
1-Adamantyl (1-Ada) 
 
1) HF (20ºC) 
scavengers (SH) 
2)TFMSA/TFA and 
scavengers (SH) 
3)Hg(OAc)2 in TFA 
(SH) 
Boc, Fmoc, 
Trt, Alloc 
 335,
343,
344,
353 
a  The Trt group should be removed first 
b The Fm should be removed first 
c Except for repetitive treatments 
d Trt should be removed first with TFA solutions 
 
9.3.2. Protecting groups removed by base 
- 9-Fluorenylmethyl (Fm).354 It is removed with base (i.e. 50% piperidine-DMF for 2 h 
or 10% piperidine-DMF overnight)355 and is very stable to strong acids such as HF. It is 
used in the Boc/Bn solid-phase strategy. It can be removed on solid phase or in solution, 
thereby yielding a disulfide because of air oxidation unless reducing thiols are 
employed. It is resistant to oxidative cleavage with iodine or Tl(TFA)3 of other Cys-
protecting groups.335  
- 2-(2,4-Dinitrophenyl)ethyl (Dnpe).356 It is removed with bases such as piperidine-
DMF (1:1) in 30-60 min, thereby yielding the disulfide bridge, or in the presence of β-
mercaptoethanol to give the free thiol. It is a less sterically hindered alternative to the 
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Fm group for the Boc/Bn strategy (specially suited to facilitate the cleavage of peptides 
with C-terminal Cys), stable to strong acids such as HF and oxidative conditions to form 
disulfide bridges with Acm (I2 or Tl(TFA)3 in TFA).  
- Benzyl (Bn). See protecting groups removed by acid. 
- 9-Fluorenylmethoxycarbonyl (Fmoc).357 Only preliminary solution studies are 
available for Cys thiol protection with Fmoc.  It seems to be more base-labile than the 
Fm group. It is removed with TEA in the presence of I2 or benzenethiol in DCM to 
yield the corresponding disulfide. These removal conditions do not affect the Nα-Fmoc 
group. 
 
Name and Structure Removal conditions Stability to 
the removal 
of 
Compatibility with 
other sulfur 
protecting groups 
Ref 
9-Fluorenylmethyl (Fm) 
 
1) 10-50% piperidine 
in DMF (S-S) 
2) DBU in DMF 
(S-S) 
Boc, Z,a Trt, 
Alloc 
Meb/Mob/Trt,b 
Acm,b  
 
335,
354,
355 
2-(2,4-Dinitrophenyl)ethyl (Dnpe) 
NO2
O2N
 
Piperidine:DMF (1:1) 
(S-S) 
in the presence of 
mercaptoethanol: (SH) 
Boc, Z,a Trt, 
Alloc 
 356 
9-Fluororenylmethoxycarbonyl (Fmoc ) 
O
O
 
TEA-benzenethiol or 
I2 (S-S) 
Boc, Z, a 
Trt, Alloc 
 357 
a Except catalytical hydrogenolysis. 
b The Fm should be removed first 
 
9.3.3. Other protecting groups 
- Acetamidomethyl (Acm).358,359 Removed by oxidative treatment with I2 or Tl(TFA)3   
to form disulfide bonds or with Hg (II) and Ag(TFMSO)344 to obtain the free thiol. It is 
comptible with both the Boc/Bn and Fmoc/tBu strategies. Nevertheless, it is partially 
removed with HF or even TFA depending on the scavengers used. 360,326 In the latter 
case, absence of water and use of TIS minimizes the removal.361  
- Phenylacetamidomethyl (PhAcm).362 It is an analog of Acm that can be removed in 
similar conditions and also by treatment with the enzyme penicillin aminohydrolase.  
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- tert-Butylmercapto (StBu).363 It is removed with thiols (benzenethiol, β-
mercaptoethanol or dithiothreitol),364 Na2SO3 in AcOH, 365 or phosphines (PBu3 or PPh3 
in CF3CH2OH).366 It is compatible with the Boc and Fmoc strategies. It is partially 
removed with HF but completely stable to TFA and to bases like piperidine.367  
- 3-Nitro-2-pyridinesulfenyl (Npys). It is removed by reducing thiols and phosphines to 
render the free thiol.368 It is stable to TFA and HF but it is not stable to the low-high 
cleavage protocol or to bases.369 It is used in the Boc/Bn strategy mainly to obtain 
disulfide bonds by nucleophilic displacement by the thiol of a free Cys. 370 
- 2-Pyridinesulfenyl (S-Pyr).371 It is used in the Boc/Bn strategy and is useful when 
orthogonal protection of unprotected fragments is required. Ligation of a free 
thiocarboxylic peptide with an S-Pyr-protected N-terminal Cys occurs at pH 2, the 
subsequent S to N migration at pH 7 and final treatment with DTT renders the final 
ligated peptide with free Cys. S-Pyr is stable to 1 M TFMSA in TFA-anisole (10:1) at 
0ºC for 2 h (cleavage conditions for the MBHA resin)  
- Allyloxycarbonyl (Alloc).163  It is removed with tributyltin hydride catalyzed by Pd(0) 
(usually Pd(PPh3)4). Because of its base lability, it is used only in the Boc/Bn solid 
phase strategy.  
- N-allyloxycarbony-N-[2,3,5,6-tetrafluoro-4-(phenylthio)phenyl]] aminomethyl 
(Fsam).372 It is an allyl-type protecting group that can be removed by palladium to 
render the free thiol both in solution and on solid phase, and is the only Cys- protecting 
group that allows a selective and easy release of the thiol on solid phase.  It is 
completely stable to TFA and piperidine and can also be removed by iodine oxidation to 
render a disulfide bridge. 
- o-Nitrobenzyl (oNB).373,374 It is a protecting group removed by photolysis (λ= 300-400 
nm) and is used mainly in the synthesis of caged peptides. 
- 4-Picolyl.375 It is removed in solution with Zn dust in AcOH to render the free thiol. It 
was initially proposed for the Boc/Bn strategy but more recently has been succesfully 
applied to the Fmoc/tBu synthesis of dihydrooxytocin, which was further oxidized to 
oxytocin.  
- Ninhydrin (Nin).376 It has been proposed as a protecting group for N-terminal Cys. It 
protects both the amino and the thiol groups by forming a thiazolidine. Stable to HF and 
TFA, it is removed with 1M Cys-OMe, 1M DIPEA in DMF for 30 min (solid phase), 
10% TFA in H2O and Zn dust (solution) as well as by reducing thiols such as Cys in 
combination with tris-carboxymethylphosphine (TCEP) (solution). It is coupled to 
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amines linked to the solid phase without using further protection at the amino group. Its 
main applications are in ligation and its combination with His(Bom) in the Boc/Bn 
strategy, which prevents tiazolidine formation after Bom removal (see His protection). 
 
Name and Structure Removal conditions Stability to 
the removal 
of 
Compatibility with 
other sulfur 
protecting groups 
Ref. 
Acetamidomethyl (Acm) 
N
H
O
 
1) I2 (S-S) 
2) Tl(TFA)3 (S-S) 
3) Ag(TFMSO) (SH) 
4) Hg (II) (SH) 
Boc, Fmoc, 
Alloc 
Meb/Mob, Trt,a 
StBu, Npys, Fm,b 
PhAcmc 
326,
344,
358,
359,
360,
361 
Phenylacetamidomethyl (PhAcm) 
N
H
O
 
1) Hg (II) (SH) 
2) penicillin 
aminohydrolase (SH) 
3) Tl (III) 
trifluoroacetate (S-S) 
4) I2 (S-S) 
Boc, Fmoc,  
Z,d Alloc 
Meb/Mob, StBu, 
Npys, Fmb, Acmc 
362 
5-tert-Butylmercapto (StBu) 
S
 
1) thiols (benzenethiol, 
β-mercaptoethanol or 
dithiothreitol) 
2) Na2SO3 in AcOH 
3) PBu3 or PPh3 in 
CF3CH2OH  
Boc, Fmoc, 
Trt 
Meb/Mob, Trt, 
Acm 
363,
364,
365,
366,
367 
3-Nitro-2-Pyridinesulfenyl (Npys) 
N
S
O2N  
1) Thiol exchange 
with a free Cys  (S-S) 
2) Reducing thiols 
(SH) 
3) PBu3 (1 eq.), H2O 
(SH) 
Boc, Z,d Trt, 
Alloc 
Meb/Mob, Trt, 
Acm 
368,
369,
370 
2-Pyridinesulfenyl (S-Pyr) 
N
S
 
Thiocarboxylic acids 
and DTT (SH) 
Boc Meb/Mob, Trt, 
Acm 
371 
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Allyloxycarbonyl (Alloc) 
O
O  
Pd(PPh3)4, Bu3SnH 
(SH) 
Boc, Trt  163 
N-allyloxycarbony-N-[2,3,5,6-
tetrafluoro-4-(phenylthio)phenyl]] 
aminomethyl (Fsam) 
O
O
N
F
F
F
S
F
 
1) Pd (0), scavengers 
(i.e. PdCl2(PPh3)2, 
Bu3SnH or Pd(PPh3)4, 
PhSiH3) 
2) I2 (S-S) 
 
  372 
o-Nitrobenzyl (oNB) 
NO2
 
Photolysis (λ= 300-
400 nm) 
Boc, Fmoc, 
Trt, Ze 
 373,
374 
4-Picolyl 
N
 
Zn dust in AcOH (SH)  Boc, Fmoc  375 
Ninhydrin (Nin) 
 
                  Nin 
1) 1M Cys-OMe, 1M 
DIPEA in DMF (solid 
phase) 
2) 10% TFA in H2O 
and Zn dust (solution)  
3) Reducing thiols 
such as Cys in 
combination with 
TCEP (solution) 
Z,d Boc  376 
a The Trt should be removed first with TFA solutions 
b The Fm should be removed first 
c The PhAcm should be removed first enzymatically 
d Except catalytical hydrogenation removal. 
e HF/anisole removal. 
 
The mercaptopropionic acid (des-amino Cys), which acts as an N-terminal capping in 
some peptides of therapeutic interest, can be introduced as a dimer.  The free thiol is 
obtained after reduction with -mercaptoethanol or Bu3P.377  
 
O
O
S
H
N
O
OH
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10. METHIONINE (Met) 
10.1. General 
The thioether funcionality of Met (Figure 22) can undergo two side reactions, oxidation 
to sulfoxide and S-alkylation. The latter can lead to the formation of homoserine lactone 
in C-terminal Met (Figure 2).378 These side reactions are favoured in acidic conditions. 
 
H2N COOH
S
Met  
Figure 22. Methionine (Met) 
 
 
Figure 23. Homoserine lactone formation after Met alkylation during HF cleavage in 
the Boc/Bn solid phase strategy. 
 
In the Fmoc/tBu strategy, Met is used unprotected in most of the cases. To prevent 
oxidation during amino acid side-chain deprotection and cleavage from the resin, 
ethylmethylsulfide or thioanisole are used.379,380 
In contrast, in the Boc/Bn strategy, free Met may not be the best option because of the 
strong acidic conditions applied mainly in the cleavage from the resin but also in the 
removal of the Boc group. Therefore, very frequently, Nα-Boc protected Met sulfoxide 
is directly used and is reduced at the end of the synthesis.    
10.2. Introduction of the protecting groups  
The sulfoxide derivatives of Met are commercially available and can be prepared via 
oxidation with H2O2. 381 
10.3. Removal: sulfoxide reduction 
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In the case of SPS, the reduction of Met(O) can be performed either during the cleavage 
or after it. In the latter case, the sulfoxide funcionality confers extra polarity to protected 
peptides, which facilitates its purification; however, it must be taken into consideration 
that sulfoxides are chiral and therefore different diastereomers will be observed. 
Several reduction methods have been used: 
1) Reduction during the low-high HF or TFMSA cleavage in the Boc/Bn strategy.  
DMS and p-thiocresol or anisole should be used as scavengers to prevent S-alkylation. 
2) N-methylmercaptoacetamide in 10% aquous acetic acid.382,383,384 It requires long 
reaction times and disulfide bridges may be reduced. 
3) TFA-NH4I-DMS.385,386,387 This method of reduction does not affect disulfide bridges 
and if there are free Cys residues, a disulfide bridge is formed during the reduction of 
the Met sulfoxide. tert-Butyl-type groups are removed during the reduction. 
Dimerization of Trp (see Trp section) can occur in the case of long reaction times as a 
result of overexposure to acidic conditions.  
4) TiCl4 (3 eq.)- NaI (6 eq.) in MeOH-acetonitrile-DMF (5:5:4).388 Although a very fast 
reduction method, it can also lead to reduction of disulfide bridges or oxidation of Trp,  
the latter caused by the I2 generated in the sulfoxyde reduction. 
5) TFA-TMSBr-EDT.389,390 In this method the reduction is carried out by addition of 
TMSBr and EDT at the end of the cleavage step. It appears to be compatible with Trp- 
containing peptides. The peptide is isolated by precipitation in diethylether.  
6) Bu4NBr in TFA. It is an alternative to method 5 in which the reduction is also carried 
out during the cleavage step.391  
7) Sulfur trioxide (5 eq.), EDT (5 eq.) in pyridine-DMF (2:8).392 In this method 
protection of hydroxyl groups is required to prevent sulfonylation.   
 
Met des-tert-butylation.  
If tert-butylation occurs during the global deprotection step, reversion to the free Met 
residue is accomplished by heating a solution of the peptide in 4% AcOH(aq) at 60-65 
ºC.393,394    
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11. HISTIDINE (HIS)  
11.1. General 
The imidazole ring of His (Figure 24) has two nucleophilic points, the π and τ-
nitrogens.395  
H2N COOH
N
NH

His
H2N COOH
HN
N

His

 
Figure 24. Histidine (His) tautomers. 
 
Unprotected His is highly prone to racemization during the coupling (Figure 25) and 
acylation during peptide synthesis followed by Nτ to α-amino migration (Figure 
26).396,397  
The basic and nucleophilic π-nitrogen is the one involved in racemization mechanisms 
and can be masked in two ways: (i) direct protection (ii) τ-nitrogen protection with 
bulky or electron-withdrawing protecting groups which reduce the basicity of the π-
nitrogen 
H2N
NH
N
O
OX H2N
O
H
N
HN
OXH Racemization
H2N
NH
N
O
OX
H
 
Figure 25. Proposed racemization mechanism of His during the coupling step. Adapted 
from 398)  
H
N
O
N
HH
HN
N
H2N
O
N
HH
N
N
O
R
O
R
Terminated peptideAcylated His  
Figure 26. Nτ to α-amino migration after acylation of His during peptide synthesis 
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Although a large number of protecting groups have been tested for His side chain 
protection, either in the π or the τ-nitrogen, the problem has still not been fully resolved, 
the situation being more critical in the case of the Boc/Bn solid phase strategy.  
The most used protecting groups are Trt for the Fmoc/tBu solid phase strategy and Dnp 
(2,4-dinitrophenyl), Bom (benzyloxymethyl) and Tos (tosyl)  for the Boc/Bn solid phase 
strategy. 
11.2. Introduction of the protecting groups 395 
Protection of the imidazole ring of His requires α-amino, and carboxylic acid protection 
with orthogonal protecting groups. In cases such as Trt, the α-amino group can be used 
unprotected and at the end of the synthesis the Nα-trityl is removed, thereby leaving the 
Nim-trityl unalterated. Generally, the reaction of the imidazole ring of His with the 
corresponding active species (halides in general) gives the N τ-protected imidazole as a 
majoritary and sometimes single product. Nevertheless, N π protection is preferred 
because, as previously mentioned, the N π is the one directly involved in His 
racemization. Thus, when possible, N π-Protection is performed by masking the τ-
nitrogen with an orthogonal protecting group, which is removed at the end of the 
synthesis of the derivative. 
11.3. Removal 
11.3.1. Protecting groups removed by acid 
N τ-protection 
- Nτ-Tosyl (Tos).399 It is removed with HF. It minimizes racemisation by reducing the 
basicity of the Nπ  by inductive effect and also because of steric hindrance. Although it 
is still quite commonly used in the Boc/Bn solid phase strategy, it  is unstable in the 
presence of Nα groups and HOBt.400,396 
- Nτ-Trityl (Trt): It is the usual protecting group for the Fmoc/tBu strategy.20,401  It is 
removed with 95% TFA but is much less acid-labile than the Nα-trityl group and cannot 
be selectively removed in the presence of  tBu groups.402 Using Nτ protection, the free Nπ 
can still catalyze racemization. However, the bulkiness of the Trt group minimizes this 
side reaction in most cases but it is still critical in particular cases such as the formation 
of ester bonds or when the amino component is sterically hindered.395 
- Nτ-Methyltrityl (Mtt) and  Nτ-monomethoxytrityl (Mmt). These are more acid-labile 
derivatives of the Trt group, they are removed with 15% and 5% TFA in DCM, 1 h. 402  
- Nτ-tert-butyloxycarbonyl (Boc).  It is only useful for the synthesis of short sequences 
via Fmoc chemistry because of its instability to prolonged piperidine treatments.401 Its 
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slightly greater acid stability compared with Trt makes it highly suitable for the 
preparation of His-containing protected peptides using a ClTrtCl resin.  
- Nτ-2,4-Dimethylpent-3-yloxycarbonyl (Doc).403 It is removed with liquid HF and is 
used in the Boc/Bn solid phase strategy. In contrast to other proposed carbamate-type 
His-protecting groups, it is very resistant to nucleophiles because of its bulkiness, 
thereby preventing Nim to Nα transfer. It is not stable to 2% hydrazine in DMF but is 
more stable to piperidine than the 2,4-dinitrophenyl  (Dnp) group (see “other protecting 
groups”) (its half life in 20% piperidine in DMF is 84 h).  
N π-protection 
- Nπ-Benzyloxymethyl (Bom). It is removed by HF, TFMSA or hydrogenolysis and is 
completely stable to bases and nucleophyles.  It has been extensively used for the 
Boc/Bn solid phase strategy. As formaldehyde is released during Bom cleavage, 
appropiate scavengers should be used to prevent formylation, methylation or the 
formation of thiazolidines when an N-terminal Cys is present.327,328  In addition, a recent 
report shows that α-amino Boc removal of Bom-protected His requires harsher 
conditions than those commonly used.404 
- Nπ-tert-Butoxymethyl (Bum).405,406It is removed by TFA and resistant to 
hydrogenolysis. Formylation during its removal can be prevented using appropiate 
scavengers in the same way as for Bom. It prevents racemization of His in the Fmoc/tBu 
strategy; however, it is not widely used because of the difficult synthesis of Fmoc-
His(π-Bum)-OH.  
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref 
Nτ-tosyl (Tos)      
N
NS
O
O
 
HF,  scavengers Boc, Trt 396,
399,
400 
Nτ-Trityl (Trt)           
N
N
 
95% TFA Fmoc, Alloc. 
 
20, 
395,
401,
402 
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Nτ-Monomethoxytrityl  (Mtt) 
N
NO
 
15 % TFA, DCM, 1 h  Fmoc, Alloc 402 
Nτ-methyltrityl (Mmt) 
N
N
 
5 % TFA, DCM, 1 h  Fmoc, Alloc 402 
Nτ-tert-butyloxycarbonyl (Boc) 
O
O NN
 
TFA, scavengers Fmoc,a Alloc 401 
Nτ-2,4-dimethylpent-3-yloxycarbonyl 
(Doc)    
O
O NN
 
HF, scavengers Boc, Z,b Trt 403 
Nπ-benzyloxymethyl (Bom) 
N
N
O
 
1) HF, scavengers 
2) TFMSA-TFA  
3) Catalytical  
Hydrogenation 
Boc, Fmoc,c Trt 327,
328,
404 
Nπ-tert-butoxymethyl (Bum) 
N
N
O
 
TFA, scavengers Fmoc, Zb 395,
396 
a Only stable to a few Fmoc removal cycles (partially labile to piperidine). 
b Catalytical hydrogenation removal. 
c Except catalytical hydrogenation removal. 
 
11.3.2. Protecting group removed by base 
Nτ-9-Fluorenylmethoxycarbonyl (Fmoc).407 It is removed with piperidine-DMF (2:8) 
and has been used for the synthesis of peptide-oligonucleotide conjugates.234 
Nτ-2,6-Dimethoxybenzoyl (Dmbz).408 It is a relatively recently developed protecting 
group for the Fmoc/tBu strategy and therefore it has not been widely used. Removed 
with ammonia solutions and stable to the removal of tert-butyl type groups, it 
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minimizes His racemization during the coupling to the same extent as Trt and also 
reduces acyl migration. 
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref 
9-Fluorenylmethoxycarbonyl (Fmoc) 
O
O NN
 
Piperidine-DMF (2:8) Boc 234,
407 
2,6-Dimethoxybenzoyl (Dmbz)   
O
N
N
O
O
 
1) 32% NH3 (aq)-
dioxane (1:1), 6 h. 
2) 32% NH3 (aq)-EtOH 
(3:1), 2 h. 
Boc, Fmoc, Trt 408 
 
 
  
11.3.3. Other protecting groups 
- Nτ-2,4-Dinitrophenyl  (Dnp).409 It is removed by thiolysis,410,411 and is stable to HF.  It 
is also commonly used in the Boc/Bn solid phase strategy. However, it also has some 
drawbacks: incomplete removal can occur in sequences rich in His and it is labile to 
nucleophiles. These features makes it incompatible with Lys(Fmoc) because after Fmoc 
removal the Dnp group can migrate to the free amino of the Lys.412 In addition, it must 
be removed before eliminating the last α-Boc group. 413 
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Nτ-2,4-dinitrophenyl  (Dnp)     
NO2
O2N
N
N
 
Thiolysis (e.g. 
thiophenol, DBU) 
Boc, Z,a Trt 409,410, 
411,412, 
413 
a Except catalytical hydrogenation removal. 
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12. SERINE (Ser), THREONINE (Thr) AND HYDROXYPROLINE (Hyp) 
12.1. General   
Amino acids containing unprotected hydroxyl funcionalities such as Ser, Thr and Hyp 
(Figure 27) can undergo side reactions such as dehydratation or O-acylation followed 
by O-N migration after amino deprotection (Figure 28).   
H2N COOH
OH
H2N COOH
OH
H
N COOH
HO
HypThrSer  
Figure 27. Serine (Ser), Threonine (Thr) and Hydroxyproline (Hyp). 
 
PGHN COOH
HO
R
O
X
PGHN COOH
O
OR
H2N COOH
OO
R
H
N COOH
OH
O
R(1) (2) (3)
Figure 28.  O-acylation followed by O-N migration after amino deprotection. (1) O-
acylation (2) Amino protecting group (PG) removal (3) O-N migration. 
 
Although, the protected derivatives are the safest way to incorporate Ser, Thr or Hyp 
into the peptide sequence, they can also be used with the free hydroxyl functionality. 
Protection is more necessary in SPS because an excess of acylating agents is used, and 
for Ser, whose primary alcohol is more prone to acylation than the secondary alcohols 
of Thr and Hyp, which have been successfully used without protection in several 
syntheses, including solid phase.414,415  Nevertheless, there are also some reports of the 
succesful use of unprotected Ser in solution phase synthesis, but care must be taken 
when choosing the activating agents.416,417 
In peptide synthesis, hydroxyl funcionalities are protected as ethers, which are more 
stable than the corresponding carbamates and esters. The most used protecting groups 
for the Boc/Bn and Fmoc/tBu strategies are Bn (benzyl) and tBu (tert-butyl) 
respectively. 
12.2. Introduction of the protecting groups  
Distinct protection methods are used depending on the kind of protecting group.  
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tBu protection is carried out via addition of isobutylene in acidic conditions.418 Bn 
protection is performed using benzyl bromide in basic conditions in the case of Ser, 
419,420 and reaction with benzyl alcohol in acidic medium in the case of Thr.421 
Bn and tBu protections can also be achieved via formation of 2,2-difluoro-1,3,2-
oxazaborolidin-5-ones by reaction of the lithium salt of Ser or the sodium salt of Thr 
with BF3. Treatment with isobutylene (tBu protection) or benzyl 2,2,2-
trichloroacetimidate (Bn protection) followed by a base treatment to destroy the 2,2-
difluoro-1,3,2-oxazaborolidin-5-one generates the desired protected derivatives.422 Trt 
and alkylsilane protection are achieved using the respective chlorides in the presence of 
a base. 423,424 
12.3. Removal  
12.3.1. Protecting groups removed by acid- Benzyl (Bn).425 It is removed with HF in 
the presence of scavengers, and is the most used protecting group for Ser and Thr in the 
Boc/Bn solid phase strategy. When many benzyl ethers are present, appropiate 
scavengers should be used to avoid benzylation of free amino acid side chains. 
- Cyclohexyl (cHx).426 It is an alternative to the benzyl group for the protection of Ser in 
the Boc/Bn solid phase strategy. It is more stable to acids and completely stable to 
catalytical hydrogenation. However, it has not been widely used. 
- tert-Butyl (tBu).418 It is removed with TFA and used mainly in the Fmoc/tBu solid 
phase strategy. tBu ethers are less acid-labile than the Boc group and some reports 
indicate that they can be used even as temporary protecting groups in the Boc/Bn solid 
phase strategy.427 
- Trityl (Trt).423  It is removed with 1% TFA. It has been shown that the same peptide 
with all the hydroxyl groups protected by Trt or tBu is obtained with better purity in the 
case of the former.428 
- tert-Butyldimethylsilyl (TBDMS).424 It is more acid-labile than the tBu group and can 
be removed selectively in the presence this group  using AcOH-THF-H2O (3:1:1) or 
TBAF.  
- Pseudoprolines: See amide backbone protection. 
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Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Benzyl (Bn) 
 
1) HF, scavengers 
2) TFMSA-TFA 
Boc, Fmoc, Trt, 
Alloc, pNZa   
 
425 
Cyclohexyl (cHx) 
 
TFMSA-TFA Boc, Fmoc, Trt, 
Alloc, pNZ  
 
426 
tert-Butyl (tBu) 
 
90% TFA-DCM Fmoc, Z,b 
Alloc, pNZ 
418,
427 
Trityl (Trt) 
 
1% TFA-DCM Fmoc, Alloc 423,
428 
tert-Butyldimethylsilyl (TBDMS) 
Si
 
1) TFA 
2) AcOH-THF-H2O 
(3:1:1), 18 h  (Ser),  2 
h (Thr) 
3) 0.1M TBAF in 
DMF, 2h (Ser), 18 h 
(Thr) 
Fmoc 424 
Pseudoprolines 
O
HN
C OH
O
R
 
R= H (Ser) or Me (Thr) 
95%  TFA and 
scavengers 
 
Fmoc, Alloc  
a Except catalytical hydrogenation removal. 
b Catalytical hydrogenation removal. 
 
12.3.2. Other protecting groups 
- tert-Butyldimethylsilyl (TBDMS). See protecting groups removed by acid. 
- tert-Butyldiphenylsilyl (TBDPS). 429,430 It is typically removed by TBAF but also by 2 
M NaOH(aq) EtOH (1:1). It is more acid-stable than TBDMS and stable to the removal 
of N-Trt, O-Trt, O-TBDMS and Boc.  
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- 4,5-Dimethoxy-2-nitrobenzyloxycarbonyl (Dmnb).431 It is a photolabile protecting 
group analogous to the corresponding Dmnb ester. Ser(Dmnb) has been used recently to 
control protein phosporyltion.432 
- Propargyloxycarbonyl (Poc).433 It is removed with [(PhCH2NEt3)2MoS4] in AcCN, 1h, 
rt. These removal conditions do not affect Boc, Z, methyl or benzyl esters,  It has 
recently been applied to the protection of Ser and Thr for peptide synthesis in solution.  
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
tert-Butyldiphenylsilyl (TBDPS) 
Si
 
1) 1 M TBAF (2-3 
eq.), THF, 1-5  h  
2) 2 M NaOH(aq) EtOH 
(1:1), 7h 
Boc, Fmoc, Trt 429,
430 
4,5-Dimethoxy-2-nitrobenzyloxycarbonyl 
(Dmnb) 
O
MeO
MeO
NO2
O  
Photolysis (visible 
blue light) 
Boc, Fmoc, Trt 431,
432 
Propargyloxycarbonyl (Poc) 
O
O
 
[(PhCH2NEt3)2MoS4] 
in AcCN, 1h. 
Boc, Fmoc, Trt  
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13. TYROSINE (Tyr) 
13.1. General 
Use of unprotected Tyr (Figure 29) can lead to acylation of the phenol group because of 
the nucleophilicity of the phenolate ion under basic conditions. In addition, the electron-
rich aromatic ring can undergo alkylation at the ortho position.  
H2N COOH
OH
Tyr  
Figure 29. Tyrosine (Tyr) 
 
The acidity of phenol group makes alkyl-type protecting groups less stable than in the 
case of Ser, Thr and Hyp. The most used Tyr-protecting groups for the Boc/Bn and 
Fmoc/tBu solid phase strategies are Bn and tBu group, respectively. 
13.2. Introduction of the protecting groups  
To protect the phenolic function of Tyr,346 both the amino and carboxylic groups must 
be protected either by forming a copper (II) chelate or using orthogonal protecting 
groups. 
tBu-protected Tyr is obtained using isobutylene in acidic medium,418 whereas with the 
other Tyr-protected derivatives the corresponding alkyl halide is used as the protecting 
agent.434,435 
13.3. Removal 
13.3.1. Protecting groups removed by acid 
- Benzyl (Bn). It is removed with HF, but can lead to benzylation of the aromatic ring of 
Tyr, and it is not stable enough to the repetitive treatments with 50% TFA in DCM to 
remove the Boc group.436 Milder removal conditions for the Boc group allow the 
synthesis of long peptides using benzyl protection.26 In solution synthesis it is usually 
removed by catalytic hydrogenation.  
- tert-Butyl (tBu). It is removed with TFA and is the most used protecting group for the 
Fmoc/ tBu strategy solid phase strategy. It is more stable than the tert-butyl ethers of 
Ser, Thr and Hyp. It is also stable to fluoride ions (TBAF) 277 
- 2,6-Dichlorobenzyl (Dcb).434 It is removed with HF and because of its major acid 
stabitlity it is an alternative to the Benzyl group for the Boc/Bn solid phase strategy. 
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- 2-Bromobenzyl (BrBn).437 It is another more acid-stable derivative of the benzyl 
group; however, it has not found as wide application as Dcb. 
- Benzyloxycarbonyl (Z).338 It is removed with HF, and protects the phenol funtionalilty 
by forming a carbonate. Although still used, it is too acid-labile to withstand repetitive 
treatments with 50% TFA to remove the Boc group. 
- 2-Bromobenzyloxycarbonyl (BrZ).434,435 It protects the phenol funcionalilty by forming 
a carbonate but unlike with other carbonates, only minor amounts of O to N transfer are 
observed. In contrast to the above mentioned Z group, BrZ is very stable to acidic 
conditions (removed with HF) and widely used for the SPS of long peptides using the 
Boc/Bn solid phase strategy.434,435 It cannot be used in the Fmoc/tBu strategy because 
being a carbonate it is very sensitive to bases and nucleophiles.438 
- 3-Pentyl (Pen).439 It is a relatively new protecting group, stable to 50% TFA, bases 
and catalytic hydrogenation and readily removed with HF.  
- tert-Butyloxycarbonyl (Boc).440 This carbonate has been used occassionally for Tyr 
side chain protection in the Boc/Bn solid phase strategy but only protects the phenol 
during the coupling and is removed with TFA along to Nα-Boc.  
- Trityl (Trt) and 2-Chlorotrityl (2-Cl-Trt). They are very acid-labile and have the 
advantage of the low electrophilicity of trityl cations. Thus, they are a better alternative 
to tBu for the synthesis of peptides containing residues prone to alkylation such as Trp 
and Met.423,441,428 Removal is carried out with 2% TFA in DCM294 
- tert-Butyldimethylsilyl (TBDMS).424 Unlike the tBu ethers, the TBDMS ether of Tyr is 
more acid-labile than the corresponding tBu ethers; however, it can be removed 
selectively with TBAF.  
- 4-(3,6,9-trioxadecyl)oxybenzyl (TEGBz or TEGBn). See 5.3.1. 
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Benzyl (Bn) 
 
1) HF and scavengers 
2) H2 cat.  
Boc, Fmoc, Trt, 
Alloc, pNZ a  
26, 
436 
tert-Butyl (tBu) 
 
35% TFA-DCM Fmoc, Z,b 
Alloc, Trt, pNZ 
277 
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2,6-Dichlorobenzyl (Dcb) 
Cl
Cl  
HF and scavengers Boc, Fmoc, Trt, 
Alloc, pNZa 
434 
2-Bromobenzyl (BrBn) 
Br
 
HF and scavengers Boc, Fmoc, Trt, 
Alloc, pNZa 
437 
Benzyloxycarbonyl (Z) 
O
O
 
HF and scavengers Boc, Trt 338 
2-Bromobenzyloxycarbonyl (BrZ) 
O
OBr
 
HF and scavengers Boc, Trt 434,
435,
438 
3-Pentyl (Pen) 
 
HF and scavengers Boc, Fmoc, Z,b 
Trt 
439 
tert-Butyloxycarbonyl (Boc) 
O
O  
TFA-DCM  440 
Trityl (Trt) 
 
2% TFA-DCM 
 
Fmoc, Alloc 294,
423,
428,
441 
2-Chlorotrityl (2-Cl-Trt) 
Cl
 
2% TFA in DCM Fmoc, Alloc 294,
423,
428,
441 
tert-Butyldimethylsilyl (TBDMS) 
Si
 
1) 35% TFA 
2) 0.1M TBAF-DMF, 
15 min. 
Fmoc 424 
4-(3,6,9-trioxadecyl)oxybenzyl (TEGBz 
or TEGBn) 
 
TFA-DCM Fmoc, Trt  
a Except catalytical hydrogenation removal. 
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b Catalytical hydrogenation removal. 
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13.3.2. Other protecting groups 
- Benzyl (Bn). See protecting groups removed by acid. 
- tert-Butyldimethylsilyl (TBDMS). See protecting groups removed by acid. 
- Allyl (Al).442,97,163 Removed with Pd (0), it is strictly orthogonal to the most common 
protecting groups. It is used both in solution strategies and SPS. 
- o-Nitrobenzyl (oNB).443 A photolabile protecting group, it has the same properties as 
the oNB ester. It has been used for the synthesis of Tyr caged peptides. 444 
- Propargyloxycarbonyl (Poc).433 (MATEIXA QUE POC, SER, P82)  It is removed 
with [(PhCH2NEt3)2MoS4] in AcCN, 1h, rt. These removal conditions do not affect Boc, 
Z, methyl or benzyl esters,  It has recently been applied to the protection of Tyr for 
peptide synthesis in solution. 
- Boc-N-methyl-N-[2-(methylamino)ethyl]carbamoyl (Boc-Nmec).445 It is a recently 
developed protecting group (see also Boc-Nmec-Hmb in 6.3.2). After removal of the 
Boc group the Nme moiety is removed with N-methylmorpholine (10 eq) in DMF/H2O 
(3:7), 4 h. 
  
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Allyl (Al) 
 
Pd(Ph3)4, scavengers Boc, Fmoc, Za  97, 
163,
442 
 o-Nitrobenzyl (oNB):  
NO2
 
Photolysis (λ=350 nm),12 h Boc, Fmoc, Trt 443,
444 
Propargyloxycarbonyl (Poc) 
O
O
 
[(PhCH2NEt3)2MoS4] in 
AcCN, 1h. 
Boc, Trt  
Boc-N-methyl-N-[2-
(methylamino)ethyl]carbamoyl 
(Boc-Nmec) 
 
i) 25-50% TFA 
ii) N-methylmorpholine (10 
eq) in DMF/H2O (3:7), 4 h 
Fmoc, Trt  
a Except catalytical hydrogenation removal. 
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14. TRYPTOPHAN (Trp) 
14.1. General  
The indole group of Trp (Figure 30) can undergo oxidation and alkylation if it is not 
protected.446  
H2N COOH
Trp
N
H
 
Figure 30. Tryptophan (Trp) 
 
Alkylation during acid treatments can be done by carbocations from released protecting 
groups or from the resin, the latter leading to irreversible bonding of the peptide to the 
support (Figure 31).447   
N
H
OH
N
H
OH
OH  
Figure 31. Alkylation of Trp by the Wang linker side products 
 
Dimerization of Trp caused by alkylation by another protonated Trp has also been 
observed (Figure 32).448,449 
N
H
H+
N
H
N
H
N
H
N
H
(1) (2)
(3)
N
H
N
H
 
Figrue 32. Mechanism of Trp dimerization. (1) Protonation, (2) Nucleophilic attack (3) 
Elimination.  
 
In the Boc/Bn strategy, the higher risk of oxidation and alkylation in acidic media 
makes the protection of Trp necessary. In addition, care must be taken when chosing the 
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scavengers in the final cleavage. For instance, thioanisole should be avoided because 
thioanisole cation adducts can alkylate Trp, and TIS, which is mainly used in the 
Fmoc/tBu strategy, should be used instead of TES to prevent reduction of the indole ring 
of Trp to indoline.450 The most used protecting group for the Boc/Bn strategy is For 
(formyl). 
In contrast, in the Fmoc/tBu strategy unprotected Trp is often used. However, in many 
cases protection is necessary. A critical example is when the peptidic sequences contain 
Arg protected by either Mtr, Pmc or Pbf groups, which after removal can react the 
indole ring in the 2 position.451,452  The most used protecting group for the Fmoc/tBu 
strategy is Boc. 
14.2. Introduction of the protecting groups 
Carbamate protection of the tert-butyl, benzyl, or phenacyl esters of Nα Boc or Z-Trp is 
easily carried out using di-tert-butyl-dicarbonate or an appropiate chloroformate in the 
presence of a tertiaty base. After that, the carboxylic acid and/or amino-protecting 
groups are removed and Nα derivatization yields the Boc and Fmoc derivatives of the 
protected Trp.453,454,455,456,457  The formyl group is introduced using an excess of formic 
acid.458 
14.3. Removal  
14.3.1. Protecting groups removed by acid 
- Formyl (For).459 Removal with HF may be slow and the use of thiols (i.e. EDT) as 
scavengers makes it faster 460 In the case of base cleavage, care must be taken with the 
reaction conditions in order to avoid free amine formylation.461,462 
- tert-Butyloxycarbonyl (Boc).455,456 It is removed with high concentrations of TFA and 
is the protecting group of choice for the Fmoc/tBu solid phase strategy. It is more stable 
than Boc α-amino protection, which can be removed in the presence of protected Trp if 
care is taken with the reaction conditions, but not as a routine procedure. Boc protection 
avoids Trp alkylation during the removal of Mtr, Pmc and Pbf from the Arg side-
chain.463,464 The N-carboxylated compound can be detected after tert-butyl removal but 
later becomes unstable thereby giving the free indole. The stability of this carbamic acid 
makes Boc-protected Trp less prone to electrophilic additions during the final 
cleavage.455,456 
- Cyclohexyloxycarbonyl (Hoc).454 It is an alternative to the formyl group for the 
Boc/Bn strategy. Its high resistance to bases makes it useful for the synthesis of 
protected peptides on base-labile resins.465 Although it is generally removed with HF in 
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the presence of p-cresol, Trp alkylation by p-cresol can occur during the removal. A 
proposed solution for this problem is the use of Fmoc-Leu or butanedithiol as 
scavengers.466 
- Mesitylene-2-sulfonyl (Mts).467Another alternative for the Boc/Bn strategy, Mts is 
removed by 1M CF3SO3H/TFA or MeSO3H but not by HF. Although it has not been 
widely applied, there are reports of its use.468 
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Formyl (For) 
 
H
O
 
1) Strong acid (HF) 
and scavengers (i.e. 
EDT) (slow) 
2) piperidine-H2O or 
DMF 
3) 1 M NH2OH, pH 9, 
2h 
 
Boc 459,
460,
461,
462 
tert-Butyloxycarbonyl (Boc)  
O
O  
 95% TFA and 
scavengers a 
 
Fmoc, Alloc 455,
456,
463,
464 
Cyclohexyloxycarbonyl (Hoc) 
O
O
 
HF, scavengers Boc, Fmoc, 
Alloc, 
454,
465,
466 
Mesitylene-2-sulfonyl (Mts) 
S
O
O
 
1) CF3SO3H/TFA  
2) MeSO3H 
 
 
 
Boc, Fmoc, 
Alloc,  
467,
468 
a The carbamic acid resulting from tert-butyl removal is quite stable. Complete decarboxylation takes 
place by treatment with 0.1M AcOH (aq) or more slowly during lyophilization in H2O. 
 
14.3.2. Protecting groups removed by base 
- Formyl (For):  see protecting groups removed by acid. 
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14.3.3. Other protecting groups 
- Allyloxycarbonyl (Alloc).457 Removed with Pd (0), its orthogonality to Boc and Fmoc 
(when removed with DBU but not when removed with piperidine) makes it potentially 
useful for both the Boc/Bn and the Fmoc/tBu solid phase strategies.  
 
Name and Structure Removal conditions Stability to the 
removal of 
Ref. 
Allyloxycarbonyl (Alloc) 
O
O  
Pd(PPh3)4, 
methylanylin in 
DMSO-THF-0.5 M 
HCl (1:1:0.5), 8h 
Boc 457 
 
15. ABBREVIATIONS 
 
AB linker 3-(4-Hydroxymethylphenoxy)propionic acid  linker  
Acm    Acetamidomethyl   
AcOH  Acetic acid 
1-Ada   1-Adamantyl  
Al   Allyl  
Alloc   Allyloxycarbonyl  
API  Active Pharmaceutical Ingredients  
Arg   Arginine  
Asn   Asparagine  
Asp   Aspartic acid  
Azoc   Azidomethyloxycarbonyl  
Bn    Benzyl  
BAL   Backbone Amide Linker  
Boc   tert-Butyloxycarbonyl  
Bom   Benzyloxymethyl   
Bpoc   2-(4-Biphenyl)isopropoxycarbonyl  
BrBn   2-Bromobenzyl  
BrPhF  9-(4-Bromophenyl)-9-fluorenyl  
BrZ    2-Bromobenzyloxycarbonyl   
Bsmoc  1,1-Dioxobenzo[b]thiophene-2-ylmethyloxycarbonyl  
Bum    tert-Butoxymethyl   
Cam   Carboxamidomethyl  
cHx    Cyclohexyl  
Cl-Z   2-Chlorobenzyloxycarbonyl  
Cpd   Cyclopropyldimethylcarbinyl  
Cys   Cysteine  
Dab   Diaminobutyric acid  
Dap   Diaminopropionic acid  
DBU  1,8-Diazabicyclo[5.4.0]undec-7-ene 
Dcb    2,6-Dichlorobenzyl   
DCHA  Dicyclohexylammonium 
DCM  Dichloromethane 
Con formato: Español (alfab.
internacional)
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Dde   (1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-ethyl)  
Ddz   α,α-Dimethyl-3,5-dimethoxybenzyloxycarbonyl 
dio-Fmoc  2,7-Diisooctyl-Fmoc 
DIPEA N,N-Diisopropylethylamine 
DKP  Diketopiperazine 
Dma   1,1-Dimethylallyl  
Dmab  4-(N-[1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-
amino)benzyl   
Dmb   2,4-Dimethoxybenzyl  
Dmcp   Dimethylcyclopropylmethyl  
DMF  N,N-Dimethylformamide 
Dmnb   4,5-Dimethoxy-2-nitrobenzyl/oxycarbonyl   
DMSO Dimethylsulfoxide  
dNBS   2,4-Dinitrobenzenesulfonyl  
Dnp    2,4-Dinitrophenyl    
Dnpe    2-(2,4-dinitrophenyl)ethyl   
Doc    2,4-Dimethylpent-3-yloxycarbonyl   
Dts   Dithiasuccinoyl 
DTT  Dithiothreitol 
EDOTn   3,4-Ethylenedioxy-2-thenyl  
Esc   Ethanesulfonylethoxycarbonyl 
Fm   9-Fluorenylmethyl 
Fmoc   9-Fluorenylmethoxycarbonyl 
Fmoc(2F)   2-Fluoro-Fmoc  
Fmoc*   2,7-di-tert-Butyl-Fmoc 
For   Formyl 
Fsam  N-allyloxycarbony-N-[2,3,5,6-tetrafluoro-4-(phenylthio)phenyl]] 
aminomethyl  
Gln  Glutamine  
Glu   Glutamic acid  
HFA   Hexafluoroacetone  
His   Histidine   
Hmb   2-Hydroxy-4-methoxybenzyl  
Hoc   Cyclohexyloxycarbonyl  
HOBt  1-Hydroxybenzotriazole 
HOSu   N-Hydroxysuccinimido  
Hyp    Hydroxyproline   
ivDde   1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-mehtylbutyl 
Lys   Lysine 
Mbh   4,4’-Dimethoxybenzhydryl  
MBHA  4-Methylbenzhydrylamine  
Meb   p-Methylbenzyl 
Men   β-Menthyl  
MeSub  2-Methoxy-5-dibenzosuberyl 
Met    Methionine  
MIM    1-Methyl-3-indolylmethyl  
mio-Fmoc  2-Monoisooctyl-Fmoc 
MIS   1,2-Dimethylindole-3-sulfonyl 
Mmt    Monomethoxytrityl   
MNPPOC  2-(3,4-Methylenedioxy-6-nitrophenyl)propyloxycarbonyl  
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Mob   p-Methoxybenzyl 
Mpe   β-3-Methylpent-3-yl 
Msc   2-(Methylsulfonyl)ethoxycarbonyl  
Mtr   4-Methoxy-2,3,6-trimethylphenylsulfonyl  
Mts   Mesitylene-2-sulfonyl 
Mtt   4-Methyltrityl  
NCA    N-carboxy anhydrides 
Nin    Ninhydrin 
NMM  N-methyl mercaptoacetamide 
NMP  1-Methylpyrrolidin-2-one 
NPPOC   2-(2-Nitrophenyl)propyloxycarbonyl  
Nps    2-Nitrophenylsulfanyl  
Npys    3-Nitro-2-pyridinesulfenyl   
Nsc    2-(4-Nitrophenylsulfonyl)ethoxycarbonyl  
α-Nsmoc  1,1-Dioxonaphtho[1,2-b]thiophene-2-methyloxycarbonyl 
NVOC  6-Nitroveratryloxycarbonyl  
oNBS   o-Nitrobenzenesulfonyl  
oNZ    o-Nitrobenzyloxycarbonyl  
Orn   Ornithine  
Pac   Phenacyl 
Pbf    Pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl   
Pen    3-Pentyl   
PhAcm   Phenylacetamidomethyl   
Phdec   Phenyldithioethyloxycarbonyl  
2-PhiPr   2-Phenylisopropyl   
pHP    p-Hydroxyphenacyl   
Pmbf    2,2,4,6,7-Pentamethyl-5-dihydrobenzofuranylmethyl  
Pmc    2,2,5,7,8-Pentamethylchroman-6-sulfonyl   
Pms    2-[Phenyl(methyl)sulfonio]ethyloxycarbonyl tetrafluoroborate   
PNA  Peptide Nucleic Acid 
pNB    p-Nitrobenzyl   
pNBS   p-Nitrobenzenesulfonyl   
pNZ    p-Nitrobenzyloxycarbonyl   
Poc    Propargyloxycarbonyl   
ΨPro   Pseudoprolines   
Pydec   2-Pyridyldithioethyloxycarbonyl  
Ser    Serine   
SPPS  Solid Phase Peptide Synthesis 
Sps    2-(4-Sulfophenylsulfonyl)ethoxycarbonyl   
SPS  Solid Phase Synthesis 
S-Pyr    2-Pyridinesulfenyl   
StBu    tert-Butylmercapto   
Sub   5-Dibenzosuberyl   
Suben   ω-5-Dibenzosuberenyl    
TAEA  tris(2-Aminoethyl)amine  
TBAF  Tetrabuthylammonium fluoride 
TBDMS   tert-Butyldimethylsilyl   
TBDPS   tert-Butyldiphenylsilyl   
tBu    tert-Butyl   
TCA  Trichloroacetic acid 
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Tce    2,2,2-Trichloroethyl   
TCEP   tris-Carboxymethylphosphine  
TCP    Tetrachlorophthaloyl   
TEA  Triethylamine 
TEAF   Tetraethylammonium fluoride 
TFA  Trifluoroacetic acid 
tfa    Trifluoroacetyl   
TFE  2,2,2-Trifluoroethanol 
TFMSA Trifluoromethanesulfonic acid 
Thr   Threonine   
Tmob   2,4,6-Trimethoxybenzyl   
TMS  Trimethylsilyl 
TMSE  Trimethylsilylethyl   
Tmsi    2-(Trimethylsilyl)isopropyl   
Tos    Tosyl   
Troc    2,2,2-Trichloroethyloxycarbonyl   
Trp    Tryptophan   
Trt    Trityl   
Tyr   Tyrosine   
Xan    9-Xanthenyl   
Z    Benzyloxycarbonyl   
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